Pathology In Depth

Library › Benign hematology: hematopoiesis and bone marrow examination, reactive marrow findings, blood and marrow infections, leukocyte morphology and platelet disorders

Benign hematology: hematopoiesis and bone marrow examination, reactive marrow findings, blood and marrow infections, leukocyte morphology and platelet disorders

Last reviewed 2026-11-17 by a board-certified pathologist. 175 references.

Normal Hematopoiesis and Bone Marrow Examination: Procedure, Processing, Normal Findings, Cytochemistry and Reporting

Definition. Hematopoiesis is the production of blood cells from hematopoietic stem cells (HSCs). After birth it takes place in the bone marrow, which also supplies the specimens for diagnosis. Bone marrow examination combines the peripheral blood, the aspirate and the trephine biopsy with immunophenotypic, cytogenetic and molecular studies in the clinical context (Lee 2008).

Related page: Automated Blood Counts, Reticulocyte Count and Peripheral Smear Review (blood counts, smear review, Howell-Jolly bodies and reference intervals) Related page: Hemoglobin Variant Analysis and Laboratory Diagnosis of Thalassemia (hemoglobin structure, oxygen dissociation and hemoglobin switching) Related page: Classification of Myeloid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry of Myeloid Neoplasms, Clonal Hematopoiesis, VEXAS Syndrome and Germline Predisposition (cellularity estimation, the 500-cell differential, blast counting and fibrosis grading) Related page: Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology (lymphopoiesis, hematogone stages, lymphocyte subsets and flow cytometry principles) Related page: B- and T-Lymphoblastic Leukemia/Lymphoma: Genetic Subtypes, Immunophenotype and Measurable Residual Disease (B-cell precursor and thymic T-cell maturation stages) Related page: Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders (hypocellular marrow, aplastic anemia and neutrophil count disorders) Related page: Laboratory Evaluation of Inborn Errors of Immunity and Secondary Immunodeficiency (severe combined immunodeficiency phenotypes) Related page: Histiocytic and Dendritic Cell Neoplasms, Hemophagocytic Lymphohistiocytosis in Tissue and Pathology of the Spleen (splenic compartments, asplenia and overwhelming post-splenectomy infection) Related page: Reactive Bone Marrow Findings: Therapy Effects, Serous Atrophy, Necrosis, Bone Disease, Storage Cells, Lymphoid Aggregates, Reactive Plasmacytosis and Thymic Hyperplasia (therapy effects, serous atrophy, necrosis, storage cells and lymphoid aggregates) Related page: Infections in Blood and Bone Marrow: Malaria, Babesiosis, Ehrlichiosis and Anaplasmosis, Other Blood Parasites, Histoplasma and Leishmania, Viral Infections and Marrow Granulomas (organisms in blood and marrow and marrow granulomas)

Hematopoietic stem cell hierarchy and growth factors

HSCs are rare, highly potent cells at the apex of a hierarchy that maintains every blood cell type. CD34 is expressed on HSCs and progenitors from early fetal development to adult marrow. The phenotype most often used to purify human HSCs is lineage-negative CD34+CD38−CD45RA−CD90+CD49f+. Adding CD49f raised the HSC frequency of the lineage-negative CD34+CD38−CD45RA−CD90+ fraction to about 1 in 10.5 cells (Rix 2022).

Thrombopoietin (TPO) is produced by the liver. It is the primary regulator of megakaryocyte progenitor expansion and differentiation and also maintains HSCs (Hitchcock 2014). Granulocyte colony-stimulating factor (G-CSF) is the principal regulator of granulopoiesis (Summers 2010).

Factor Main source Target and effect Source
Erythropoietin (EPO) Renal EPO-producing cells; hepatic EPO production rises when hepatic prolyl hydroxylases are deleted in mice Erythroid progenitors; production rises when hypoxia-inducible factor is activated Hou 2026
TPO Liver Megakaryocyte progenitors (expansion, differentiation and endomitosis) and HSC maintenance, through the receptor MPL (c-Mpl) Hitchcock 2014; Machlus 2013
G-CSF Produced in response to macrophage ingestion of apoptotic neutrophils in tissues Commitment of progenitors to the myeloid lineage, proliferation of granulocytic precursors, shorter marrow transit time and release of mature neutrophils Summers 2010
IL-7 Bone marrow stromal cells Proliferation of developing B-lineage cells; loss-of-function IL7R variants cause autosomal recessive T−B+NK+ severe combined immunodeficiency, about 10% of human SCID Clark 2014; Ward 2026

Eosinophilopoiesis. IL-5, IL-3 and GM-CSF all take part in eosinophil production. Up-regulation of the IL-5 receptor α chain on progenitors indicates eosinophil lineage commitment, and IL-5 induces terminal eosinophil differentiation (Salter 2021).

Feedback control of TPO. In the classic model, circulating TPO is cleared by MPL on platelets and megakaryocytes, so the plasma TPO concentration is inversely proportional to the total MPL mass. In mice, platelets lose sialic acid as they age, and binding of desialylated platelets to the hepatic Ashwell-Morell receptor induces hepatic TPO transcription and translation (Grozovsky 2015).

Erythropoiesis, granulopoiesis and megakaryopoiesis: stages and kinetics

Lineage Maturation sequence and key events Kinetics Source
Erythroid Proerythroblasts undergo 4–5 mitoses with decreasing cell and nuclear size and leave the cell cycle at the orthochromatic erythroblast stage. Enucleation produces a pyrenocyte (the expelled nucleus), which marrow macrophages engulf, and an anucleate reticulocyte About 2 × 10¹¹ red cells are produced per day in an adult. Red cells circulate for an average of about 115 days (range 80–130 days, depending on the method) Newton 2024; Mock 2014
Granulocytic Myeloblast, promyelocyte, myelocyte, metamyelocyte, band and segmented neutrophil. Promyelocytes and myelocytes form the mitotic pool. Metamyelocytes, bands and segmented neutrophils do not divide; they form the post-mitotic pool, which is the marrow reserve. Metamyelocytes and bands have a kidney-shaped nucleus Transit through the post-mitotic pool takes 4–6 days. Circulating half-life is 6–8 hours. Basal production is 5–10 × 10¹⁰ neutrophils per day Summers 2010; Malengier-Devlies 2021
Megakaryocytic TPO-dependent differentiation; endomitosis (DNA replication without cell division) to a DNA content of up to 128n in one polylobulated nucleus; extension of 10–20 proplatelets into marrow sinusoids; the nucleus is extruded and phagocytosed Maturation and platelet release take about 5 days. About 10¹¹ platelets are made each day, and each survives 7–10 days Machlus 2013

Marginated and circulating neutrophil pools. The total blood granulocyte pool is about 65 × 10⁷ cells/kg, with 49% in the circulating pool and 51% in the marginated pool (Summers 2010). Marginated pools are found in the spleen, liver and bone marrow. Exercise and adrenaline shift cells from the marginated to the circulating pool. Prednisolone enlarges both pools. Bacterial endotoxin enlarges the total pool by increasing marrow release (Summers 2010). Release from the marrow follows loss of the CXCR4–SDF-1 and VLA-4–VCAM-1 interactions, and G-CSF inhibits the CXCR4–SDF-1 retention axis (Summers 2010).

Fetal and neonatal hematopoiesis: yolk sac, liver and bone marrow

Site Timing and features Source
Yolk sac Blood islands with erythroid cells appear in human embryos at 17 days. Mast cells and NK and innate lymphoid cell precursors are present Yamane 2020; Popescu 2019
Fetal liver Site of definitive hematopoiesis, with self-renewal and differentiation of HSCs and multipotent progenitors. Its output shifts during gestation away from a predominantly erythroid composition Popescu 2019
Fetal bone marrow Hematopoiesis first appears at 11–12 weeks after conception. The full blood and immune repertoire is established within 6–7 weeks early in the second trimester. Granulocytes, eosinophils and dendritic cell subsets first appear here, and B lymphocytes expand more than in the fetal liver of the same age Jardine 2021

Developmental hematopoiesis consists of multiple, partially overlapping waves in extraembryonic and intraembryonic tissues. Human HSCs arise from a specialized arterial endothelium in the aorta-gonad-mesonephros region (Calvanese 2023). Megakaryocytes arise from HSCs that reside mainly in the bone marrow and, during early development, in the yolk sac, fetal liver and spleen (Machlus 2013). Hemoglobin switching from embryonic to fetal and adult hemoglobins is taught in Hemoglobin Variant Analysis and Laboratory Diagnosis of Thalassemia. Neonatal reference intervals are taught in Automated Blood Counts, Reticulocyte Count and Peripheral Smear Review.

Spleen function, hyposplenism and the pitted red cell count

Beyond the filtration and antibody functions taught in Histiocytic and Dendritic Cell Neoplasms, Hemophagocytic Lymphohistiocytosis in Tissue and Pathology of the Spleen, the red pulp stores iron, red cells, platelets and plasma cells and supports extramedullary hematopoiesis, and marginal zone B cells respond to T-independent type 2 antigens of encapsulated bacteria (de Porto 2010).

Tests of splenic function. Pits are structures in the red cell membrane seen by interference phase microscopy. They are present in 0%–4% of red cells with normal splenic function. A count above 4% is associated with hyposplenism, and asplenia or clinically relevant hyposplenism usually gives 15%–70%. A cutoff of 15% has been proposed for significant splenic dysfunction (de Porto 2010). Howell-Jolly bodies correlate poorly with scintigraphic clearance and miss mild hyposplenism. Scintigraphy with technetium-99m-labelled, heat-altered autologous red cells is the most reliable method, and sulfur colloid scintigraphy is limited by high liver uptake. The pitted red cell percentage is the first-line screen, and an abnormal result is confirmed by scintigraphy (de Porto 2010).

Causes of hyposplenism. Causes include congenital asplenia, sickle cell disease (SS, SC and S/β-thalassemia), celiac disease, dermatitis herpetiformis, inflammatory bowel disease, Whipple disease, alcoholic liver disease and cirrhosis, systemic lupus erythematosus, rheumatoid arthritis, bone marrow transplantation, graft-versus-host disease, lymphomas, splenic artery or vein thrombosis and the normal or premature neonate (de Porto 2010).

Patients with functional hyposplenism share the risk of overwhelming post-splenectomy infection (de Porto 2010).

Bone marrow aspiration and trephine biopsy: indications, sites and safety

Indications in people with HIV. Indications include lymphadenopathy or a mass unsuitable for biopsy, imaging that suggests tuberculosis or lymphoma, unexplained cytopenias, an unexplained leukoerythroblastic film with or without teardrop cells, and blasts or lymphoma cells in the blood (Opie 2024). Marrow evaluation of a suspected myeloid neoplasm is taught in Classification of Myeloid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry of Myeloid Neoplasms, Clonal Hematopoiesis, VEXAS Syndrome and Germline Predisposition.

Sites. In one series, aspirates and trephine biopsies were taken from the posterior superior iliac spine, and the trephine was taken 0.5–1 cm from the aspiration site to avoid a hemorrhagic biopsy (Goyal 2014). The oldest reference differential counts came from sternal punctures, a procedure that is largely abandoned today (Parmentier 2020).

Trephine length. In diffuse large B-cell lymphoma, 20% of biopsies shorter than 20 mm and 35% of biopsies of 20 mm or more showed lymphoma. A single-site 20-mm biopsy examined at 4 or more levels removed the need for bilateral sampling (Campbell 2003). In a second series, lymphoma detection rose with preprocessing length to a maximum at 17–20 mm, with no further gain beyond 20 mm (Goyal 2014). Two unilateral cores with a total length above 25 mm are recommended in people with HIV (Opie 2024). The trephine length required for aplastic anemia is given in Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders.

Complications. A British Society for Haematology survey recorded 26 adverse events, including 1 death, among an estimated 54,890 biopsies between 1995 and 2001. Hemorrhage was the most frequent and most serious event (Bain 2003). The main risk factors for hemorrhage, in order of frequency, were a myeloproliferative neoplasm, aspirin, other platelet dysfunction and thrombocytopenia (Bain 2005). Warfarin, disseminated intravascular coagulation and obesity were also associated with hemorrhage (Bain 2003).

Dry tap. A dry tap is a failed aspiration of marrow particles. In 1,060 paired aspirates and biopsies, 125 (11.8%) aspirates were aparticulate and hemodiluted. In 20 (16%), an adequate trephine biopsy attributed the dry tap to technique. In 105 (84%), marrow disease was present that plausibly explained it. Acute leukemia was the most common cause (32.8%) (Singh 2025). Marrow necrosis as a cause of a dry tap is described in Reactive Bone Marrow Findings: Therapy Effects, Serous Atrophy, Necrosis, Bone Disease, Storage Cells, Lymphoid Aggregates, Reactive Plasmacytosis and Thymic Hyperplasia.

Specimen allocation and processing: smears, imprints and decalcification

Opie 2024 recommends the following allocation for marrow biopsies in people with HIV; the trephine row gives one published processing protocol.

Specimen Allocation or processing Source
Aspirate smears Routine stains of the glass slides, including an iron stain Opie 2024
Touch imprints of the trephine Stained in place of aspirate smears when the aspirate is dry Opie 2024
Flow cytometry 5 mL of aspirate in EDTA for all new or possible lymphoma or leukemia, kept at room temperature to reach the referral laboratory within 24 hours Opie 2024
Cytogenetic karyotype Aspirate in a heparin tube or cytogenetic culture medium for all new or possible lymphoma or leukemia Opie 2024
Mycobacterial and fungal cultures Aspirate for all lymphoma staging and possible lymphoma or leukemia in people with HIV Opie 2024
Trephine biopsy Fixed in 10% neutral buffered formalin and decalcified in 5.5% EDTA for 24 hours in one published protocol; length measured after decalcification Goyal 2014

Clot sections. Sections of the clotted aspirate need no decalcification, which improves antigen expression for immunohistochemistry and FISH, and they add sensitivity to the aspirate and trephine (Cantadori 2019).

Decalcification and DNA. Formic acid decalcification of trephines degrades DNA. EDTA decalcification preserves DNA well enough for amplification and sequencing of relatively long PCR products (Wickham 2000). In paired bilateral trephines, EDTA decalcification preserved nuclear immunohistochemical staining and gave better DNA yield and integrity than hydrochloric acid, but needed the longest decalcification time (Choi 2015).

Normal bone marrow: cellularity by age, M:E ratio and normal variation

Cellularity assessment in suspected neoplasms is taught in Classification of Myeloid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry of Myeloid Neoplasms, Clonal Hematopoiesis, VEXAS Syndrome and Germline Predisposition. In 570 benign staging and healthy donor marrows from patients 1 to 93 years of age, adult cellularity declined by about 3% per decade, including after the seventh decade. The 90% reference interval for normocellularity was 30%–75% from 18 to 90 years (Wong 2024). The range for patients younger than 20 years is the earlier one of Friebert et al (1998), quoted by Wong 2024; the adult ranges are Wong's recommendations.

Age Normocellular range (mean ± SD) Source
<20 years 45%–85% (65% ± 20%) Friebert 1998, cited by Wong 2024
20–40 years 40%–70% (55% ± 15%) Wong 2024
40–60 years 35%–65% (50% ± 15%) Wong 2024
>60 years 30%–60% (45% ± 15%) Wong 2024

The "100 minus age" rule. The linear model of 100% minus the age in decades predicts a faster decline than the measured one. Patients older than 70 years showed no significant further decrease from those aged 60 to 69 years (Wong 2024).

Reference differential count. Aspirates from 236 healthy unrelated marrow donors aged 18–51 years were each counted by 3 observers (600 cells per sample). The table gives the 2-sided 95% reference ranges (Parmentier 2020).

Cell or ratio 95% reference range (median) Source
Erythroblasts, all stages 15.8%–46.2% (32.0%) Parmentier 2020
Granulocytic cells, all stages 34.8%–66.3% (49.5%) Parmentier 2020
Myeloblasts 0%–5.0% (1.5%) Parmentier 2020
Promyelocytes 0%–5.5% (1.0%) Parmentier 2020
Myelocytes 5.8%–24.0% (13.5%) Parmentier 2020
Metamyelocytes 1.0%–12.0% (4.5%) Parmentier 2020
Band neutrophils 6.5%–26.2% (14.5%) Parmentier 2020
Segmented neutrophils 2.5%–19.7% (9.5%) Parmentier 2020
Eosinophils 0.5%–7.0% (2.5%) Parmentier 2020
Basophils and mast cells 0%–1.5% (0%) Parmentier 2020
Monocytes 0%–6.0% (2.0%) Parmentier 2020
Lymphocytes 5.5%–23.2% (13.2%) Parmentier 2020
Plasma cells 0%–7.0% (2.3%) Parmentier 2020
M:E ratio (myeloid plus monocytic cells to erythroid cells) 0.8–4.1 (1.6) Parmentier 2020

Men had significantly more erythropoiesis than women and therefore lower M:E ratios. Body mass index also affected the counts, and age did not. One to 3 megakaryocytes per low-power field defined normal megakaryopoiesis, which was present in 89% of donors. Agreement between observers was greater for assignment of cells to a lineage than for individual maturation stages (Parmentier 2020).

Aspirates of healthy subjects. In posterior iliac aspirates from 50 healthy volunteers, the M:E ratio and the neutrophil percentage were significantly higher in women, and the erythroid component was lower (Bain 1996). Storage iron above trace amounts was present in all 28 evaluable men and 11 of 17 evaluable women. The proportion of erythroblasts with iron granules ranged from 3% to 69% in subjects with more than trace storage iron. Minor dyserythropoietic features were common. Nineteen of 50 subjects had 1 or 2 dysplastic megakaryocytes, and granulocytic dysplasia was absent (Bain 1996). Iron grading, ring sideroblasts and the iron stain as a reference standard are taught in Microcytic Anemias and Iron Studies and Myelodysplastic Neoplasms: WHO 5th Edition and ICC Types, Dysplasia Morphology, TP53-Mutated Myeloid Neoplasms and Prognostic Scoring.

Bone marrow reporting: ICSH 2008 and ICSH 2026 integrated reports

Current guidance (ICSH 2026). The International Council for Standardization in Haematology (ICSH) guidance on bone marrow examination and reporting extends and refines the 2008 guideline. It covers the morphology of aspirate and trephine specimens, flow cytometry, immunohistochemistry and molecular genetic testing. Its central principle is the integrated report, which synthesizes every modality in the clinical context and aligns the diagnosis with current international classifications. Automated digital microscopy and computational decision support are outside its scope (Erber 2026).

Previous rule (ICSH 2008). The aspirate and trephine are complementary. The final interpretation integrates the peripheral blood, aspirate and trephine findings with immunophenotyping, cytogenetic and molecular results in the clinical context (Lee 2008).

Synoptic reporting. Indian College of Hematologists and Indian Society of Hematology and Blood Transfusion (ICH-ISHBT) 2026 synoptic reports pair an aspirate and imprint report, which integrates the blood film and recent counts, with a trephine report that states the need for immunophenotypic, cytogenetic and molecular studies (Pati 2026a; Pati 2026b). The CAP template for suspected myeloid neoplasms is taught in Classification of Myeloid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry of Myeloid Neoplasms, Clonal Hematopoiesis, VEXAS Syndrome and Germline Predisposition.

Cytochemical stains: reactions, lineage and current role

Cytochemistry identifies lineage by enzyme activity or stored material. Cytochemical criteria for AML subtypes are taught in AML, Myelodysplasia-Related, AML Defined by Differentiation, Myeloid Neoplasms Post Cytotoxic Therapy and of Down Syndrome, Myeloid Sarcoma, BPDCN and Acute Leukemias of Ambiguous Lineage.

Stain Reaction in normal and leukemic cells Lineage indicated Source
Myeloperoxidase (MPO) Strong in granulocytic cells; usually negative in monoblasts; slight scattered positivity in promonocytes (Varotto 2022); weak and inconsistent in monocytes (Zini 2026) Granulocytic Varotto 2022; Zini 2026
Sudan black B (SBB) Typically negative in monoblasts; negative in PAS-positive lymphoblastic leukemias Negative in monoblasts and in PAS-positive lymphoblastic leukemias Varotto 2022; Snower 1991
Naphthol AS-D chloroacetate esterase (specific esterase) Typically negative in monoblasts Neutrophilic (granulocytic) Varotto 2022; Zushi 2018
Nonspecific esterase (α-naphthyl acetate or α-naphthyl butyrate esterase) Strong in monoblasts and promonocytes; negative or weak in 10%–20% of acute monocytic leukemias (Varotto 2022). α-Naphthyl butyrate esterase is the more specific and α-naphthyl acetate esterase the more sensitive for monocytes (Zini 2026). Sodium fluoride diminished α-naphthyl butyrate esterase staining in every monocytic leukemia studied (Zushi 2018) Monocytic Varotto 2022; Zini 2026; Zushi 2018
Periodic acid-Schiff (PAS) Blocks or coarse granules in ≥5% of blasts: 15 of 29 lymphoblastic and 4 of 21 myeloblastic leukemias. All PAS-positive myeloblastic leukemias were positive with at least 1 other stain, and the 3 with >10% PAS-positive blasts were acute monoblastic leukemias Lymphoblastic, when MPO, SBB and α-naphthyl butyrate esterase are negative Snower 1991
Tartrate-resistant acid phosphatase (TRAP) Expressed by hairy cell leukemia cells and demonstrated on trephine sections; absent in hairy cell leukemia variant (ICC term; splenic B-cell lymphoma/leukemia with prominent nucleoli in WHO-HAEM5) Hairy cell leukemia Kreitman 2018; Alaggio 2022
Perls Prussian blue Storage iron and sideroblasts Iron stores Bain 1996

WHO-HAEM5 and ICC 2022 retain cytochemistry for separating monocytic proliferations from other neoplasms when morphology and flow cytometry are confounding (Zini 2026).

PAS sensitivity and specificity. PAS alone had a sensitivity of 52% for lymphoblastic leukemia. PAS positivity combined with negative MPO, SBB and α-naphthyl butyrate esterase reactions had 52% sensitivity and 100% specificity (Snower 1991).

MPO by cytochemistry and by flow cytometry. Enzyme cytochemistry and 3-color flow cytometry agreed in 27 of 30 acute leukemias. Flow cytometry detected MPO in 1 of 4 cases of minimally differentiated AML and 2 of 5 cases of acute monoblastic leukemia in which cytochemistry detected none (Nguyen 1998).

Reactive Bone Marrow Findings: Therapy Effects, Serous Atrophy, Necrosis, Bone Disease, Storage Cells, Lymphoid Aggregates, Reactive Plasmacytosis and Thymic Hyperplasia

Definition. Reactive marrow findings are non-neoplastic changes in the bone marrow caused by therapy, nutrition, ischemia, metabolic bone disease, storage disorders, infection or immune stimulation. Several of them mimic neoplasms: pseudo-Gaucher cells, benign lymphoid aggregates and polyclonal plasmacytosis. Lymphoid aggregates and plasmacytosis are separated from neoplasms by immunohistochemistry, flow cytometry and clonality studies (Maccio 2022; Evans 2022).

Related page: Normal Hematopoiesis and Bone Marrow Examination: Procedure, Processing, Normal Findings, Cytochemistry and Reporting (procedure, processing, normal cellularity and cytochemistry) Related page: Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders (aplastic anemia and the hypocellular marrow) Related page: Infections in Blood and Bone Marrow: Malaria, Babesiosis, Ehrlichiosis and Anaplasmosis, Other Blood Parasites, Histoplasma and Leishmania, Viral Infections and Marrow Granulomas (organisms in marrow, marrow granulomas, and reactive plasmacytosis in HIV infection and visceral leishmaniasis) Related page: Classification of Myeloid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry of Myeloid Neoplasms, Clonal Hematopoiesis, VEXAS Syndrome and Germline Predisposition (reticulin and collagen fibrosis grading) Related page: Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology (hematogones and flow cytometry of lymphoid infiltrates) Related page: Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia (lymphoma patterns in marrow) Related page: Plasma Cell Neoplasms and Diseases with Paraproteins: MGUS, Smoldering and Plasma Cell Myeloma, Plasmacytoma, Plasma Cell Leukemia, Amyloidosis, POEMS Syndrome and Heavy Chain Diseases (clonal plasma cells) Related page: Lymph Node Pathology: Normal Structure, Triage, Reactive and Infectious Lymphadenopathy, Castleman and IgG4-Related Disease, and Metastases to Lymph Node and Marrow (reactive lymphadenopathy patterns, dermatopathic lymphadenopathy, Toxoplasma and cat-scratch lymphadenitis, Kikuchi-Fujimoto and Castleman disease, autoimmune lymphadenopathy, nodal inclusions, and metastatic tumor in marrow including neuroblastoma) Related page: Histiocytic and Dendritic Cell Neoplasms, Hemophagocytic Lymphohistiocytosis in Tissue and Pathology of the Spleen (Rosai-Dorfman disease, hemophagocytic lymphohistiocytosis in tissue and non-neoplastic splenic lesions) Related page: Granulomatous Lymphadenitis (Cytology) (granulomatous lymphadenitis on FNA) Related page: Newborn Screening and Biochemical Genetics: Amino Acid, Organic Acid, Fatty Acid Oxidation, Urea Cycle, Lysosomal and Peroxisomal Disorders (lysosomal enzyme testing and the Gaucher disease biomarkers lyso-Gb1 and chitotriosidase) Related page: Pharmacogenomic Genotyping, Identity and Parentage Testing with Short Tandem Repeats, Engraftment Monitoring and Molecular Infectious Disease Testing (chimerism analysis after hematopoietic cell transplantation) Related page: HLA Typing, HLA Antibody Testing, Crossmatch and Platelet and Neutrophil Antibody Testing (chimerism testing methods)

Marrow after chemotherapy, growth factors and other drugs

Post-chemotherapy regeneration. In 60 children with acute lymphoblastic leukemia, cellularity, blast percentage and the leukemic index fell significantly from diagnosis to day 14 of induction from myelosuppression. The day 28 marrow showed regeneration with increased cellularity (Kushwaha 2014). In 155 post-induction marrows, the marrow was hypercellular in 55.9% of AML and normocellular in 56.3% of ALL, and regenerative hematopoiesis was present in 37.4% of AML and 88.5% of ALL. Serous atrophy and stromal edema were associated with delayed count recovery lasting 1 to 5 months. The trephine detected residual blasts in 4 patients whose aspirate showed remission (Ayyanar 2021). In 12 children and adults with ALL evaluated after induction or for suspected relapse, blast-like mononuclear cells made up 6% to 26% of the aspirate and proved to be hematogones by flow cytometry (Singh 2023). Regenerating B-cell precursors (hematogones) and their separation from residual lymphoblasts are taught in Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology and B- and T-Lymphoblastic Leukemia/Lymphoma: Genetic Subtypes, Immunophenotype and Measurable Residual Disease.

Granulocyte colony-stimulating factor (G-CSF). G-CSF physiology is taught in Normal Hematopoiesis and Bone Marrow Examination: Procedure, Processing, Normal Findings, Cytochemistry and Reporting. In 53 patients given G-CSF or GM-CSF for neutropenia, the blood showed neutrophilia with a prominent left shift, increased azurophilic granulation and Döhle bodies. Circulating myeloblasts did not exceed 2% of leukocytes, and 54% of patients had a leukoerythroblastic film. Early in therapy the marrow showed relative neutrophil hyperplasia with a marked increase in promyelocytes and myelocytes. With continued therapy the M:E ratio normalized, promyelocytes decreased, and myelocytes and band neutrophils increased. All 13 nonresponders had virtually acellular trephines (Schmitz 1994). G-CSF is a recognized drug-related cause of marrow necrosis (Palo 2026).

Thrombopoietin receptor agonists (TPO-RAs). In 54 children with chronic immune thrombocytopenia who had at least 6 months of TPO-RA therapy and a marrow biopsy for suboptimal response or loss of efficacy, 14 (25.9%) had clinically significant fibrosis (MF ≥2) in this selected cohort. TPO-RA overdose (adjusted OR 4.41) and the number of switches between agents (adjusted OR 4.00) were the only independent predictors. Of 8 children with MF ≥2 who had a follow-up biopsy, all 5 who stopped TPO-RAs showed regression (2 to MF-0, 3 to MF-1), and all 3 who continued had persistent MF ≥2 (Ma 2026). Fibrosis grading is taught in Classification of Myeloid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry of Myeloid Neoplasms, Clonal Hematopoiesis, VEXAS Syndrome and Germline Predisposition.

Growth factor hyperplasia mimicking a myeloproliferative neoplasm. TPO-RAs, G-CSF and EPO induce hyperplasia of the megakaryocytic, granulocytic and erythroid lineages, respectively, and can mimic a myeloproliferative neoplasm on the trephine. Tumors that produce these factors, such as hepatocellular carcinoma, renal cell carcinoma, mesothelioma and soft tissue sarcomas, can do the same (Menter 2025).

Other drug effects.

  • Lenalidomide. Patients with multiple myeloma on lenalidomide maintenance can have a reactive polyclonal marrow plasmacytosis, shown by immunophenotyping (Hassoun 2017).
  • Ponatinib. In a single case report, ponatinib therapy was followed by gelatinous transformation with fat atrophy and Alcian blue-positive extracellular material (Lazzi 2025).

Serous atrophy (gelatinous transformation): causes and morphology

Morphology. Gelatinous transformation, also known as starvation marrow or serous fat atrophy, shows focal hypoplasia of adipocytes and hematopoietic cells with extracellular gelatinous material composed mainly of hyaluronic acid-based mucopolysaccharides (Mashimoto 2024). The material is positive with Alcian blue at pH 2.5 and with PAS (Palo 2026).

Anorexia nervosa. Marrow findings in anorexia nervosa are graded in 5 levels: normal, hypoplastic, aplastic, partial gelatinous transformation and complete gelatinous transformation (Mashimoto 2024). Hypoplastic and aplastic marrows often give a dry tap. Gelatinous marrow usually does not, because the gelatinous material is aspirated. Marrow adipocyte volume rises in mild-to-moderate anorexia nervosa, and gelatinous transformation in severe disease accompanies collapse of the adipocyte tissue (Mashimoto 2024).

Causes beyond starvation. A 2024 review proposes that malignancy, infection and inflammatory conditions contribute to gelatinous transformation in addition to nutrient deficiency (Gunaratne 2024). The largest study cited in a 2017 review found an incidence of 0.2% among 80,000 marrow samples. Among 522 published cases, anorexia or malnutrition (147) and malignancy (109) were the most frequent associations. In HIV infection, gelatinous transformation was reported in 22 of 75 patients in one series, and cytokines such as IL-1, IL-2 and tumor necrosis factor are the proposed mechanism (Shergill 2017). Gelatinous transformation occurs in visceral leishmaniasis (Mangat 2026).

Bone marrow necrosis: causes, morphology and differential diagnosis

Marrow necrosis destroys hematopoietic tissue and marrow stroma and usually spares cortical bone. It is reported in about 0.3%–2% of marrow biopsies and results mainly from ischemic injury (Palo 2026).

Category Examples Mechanism Source
Hematologic neoplasms ALL, AML, high-grade lymphoma, CML in blast phase Infiltration, microvascular compression, cytokine-mediated endothelial injury Palo 2026
Metastatic tumors Carcinomas of prostate, breast, lung, stomach and pancreas; melanoma Infiltration with ischemia Palo 2026
Hemoglobinopathies and other hematologic disorders Sickle cell disease, severe hemolytic anemia, myeloproliferative neoplasms Vaso-occlusion Palo 2026
Infections Bacterial sepsis, tuberculosis, Aspergillus, Candida, viral infections Cytokine release, septic microvascular thrombosis Palo 2026
Drugs Chemotherapy, interferon, G-CSF, some antibiotics Cytotoxicity or vascular injury Palo 2026
Autoimmune and systemic conditions Antiphospholipid syndrome, systemic lupus erythematosus, disseminated intravascular coagulation Microthrombi Palo 2026
Metabolic and toxic conditions Severe hypoxia, alcoholism, severe malnutrition Impaired oxygen delivery Palo 2026

Hematologic neoplasms, particularly acute leukemias and high-grade lymphomas, are the most common cause group (Palo 2026).

Clinical and laboratory findings. Severe bone pain, most often axial, is the most common symptom. Cytopenias, a leukoerythroblastic film and a markedly raised lactate dehydrogenase are typical. Aspiration often gives a dry tap or amorphous debris (Palo 2026).

Morphology. The trephine shows loss of marrow architecture and replacement by eosinophilic, granular or amorphous debris with ghost outlines of hematopoietic and stromal cells. Trabecular bone is usually preserved. Inflammatory cells may border the necrotic zones, and residual viable islands can show the underlying disease. Necrosis is graded by extent: grade I, <20% of the marrow; grade II, 20%–50%; grade III, >50% (Palo 2026).

Lesion Distinguishing feature Source
Marrow necrosis Amorphous eosinophilic debris with ghost cells; trabeculae preserved; Alcian blue and PAS negative Palo 2026
Bone infarction Necrosis of both marrow and trabecular bone Palo 2026
Osteomyelitis Suppurative inflammation with reactive bone formation Palo 2026
Post-therapy marrow Hypocellularity and stromal change without an amorphous necrotic background Palo 2026
Aplastic anemia Hypocellular marrow replaced by fat with intact stroma; no necrotic debris or ghost cells Palo 2026
Gelatinous transformation Fat atrophy and hypocellularity with hyaluronic acid-rich material that is Alcian blue (pH 2.5) and PAS positive Palo 2026

Metabolic bone disease in marrow trephine biopsies

Disorder Trephine findings Mechanism Source
Paget disease of bone Irregular cement lines in a mosaic (jigsaw) pattern; increased osteoclasts with resorption pits and increased osteoblast activity; marrow fibrosis (Lee 2026). Increased vascularity (Ralston 2019) Mutations that impair p62 binding to ubiquitin increase RANKL-induced NF-κB signaling and osteoclast activity Lee 2026; Ralston 2019
Renal osteodystrophy (high turnover, with secondary hyperparathyroidism) Irregular trabeculae lined by numerous osteoblasts, increased osteoid, multinucleated osteoclasts in enlarged resorption bays, and paratrabecular reticulin and trichrome fibrosis; focal lytic lesions can mimic plasma cell myeloma on imaging Chronic kidney disease–mineral and bone disorder with accelerated bone turnover; raised PTH, alkaline phosphatase and phosphate Hanley 2026
Hyperparathyroidism (osteitis fibrosa cystica) Generalized bone resorption, fibrous replacement of marrow, cystic change and brown tumors of fibrovascular tissue with multinucleated giant cells, hemorrhage and hemosiderin Sustained PTH excess increases osteoblast RANKL and osteoclast activation Abu Isneina 2026
Osteopetrosis Increased bone density with impaired marrow function and marrow failure Defective osteoclastic bone resorption; CLCN7 encodes an osteoclast chloride channel needed for acidification Meena 2026

Brown tumors overlap histologically with giant cell tumor and aneurysmal bone cyst (Abu Isneina 2026). Marrow fibrosis in primary hyperparathyroidism occurs with markedly raised PTH and alkaline phosphatase and reverses after parathyroidectomy (Abdelfadiel 2026). Biochemical diagnosis of Paget disease and renal osteodystrophy, and the indications for bone biopsy in chronic kidney disease, are taught in Calcium, Parathyroid Hormone, Vitamin D, Magnesium and Phosphate.

Storage cells and pseudo-Gaucher cells in marrow

Cell Morphology Disorder and defect Source
Gaucher cell Large macrophage with an eccentric nucleus of condensed chromatin and "crumpled paper" cytoplasm with striations; glucosylceramide aggregates form fibrillar twisted ribbons on electron microscopy Gaucher disease; GBA1 (1q21) variants reduce glucocerebrosidase activity, and glucosylceramide accumulates in macrophages Camou 2025
Foamy histiocyte Abundant cytoplasm filled with small vacuoles; numerous on every diagnostic marrow smear in acid sphingomyelinase deficiency (ASMD) and Niemann-Pick disease type C (Girard 2024) ASMD (Niemann-Pick disease types A and B): autosomal recessive SMPD1 variants with reduced sphingomyelinase activity. Niemann-Pick disease type C is a separate entity (Vélez Pinos 2023) Girard 2024; Vélez Pinos 2023
Sea-blue histiocyte Histiocytes with sea-blue granules on May-Grünwald-Giemsa stain ASMD, mainly type B: present in 7 of 14 diagnostic ASMD and Niemann-Pick type C marrows (Girard 2024); acquired sea-blue histiocytosis with pancytopenia during chronic parenteral nutrition (Bourrienne 2024) Girard 2024; Bourrienne 2024
Pseudo-Gaucher cell Gaucher-like macrophages without enzyme deficiency Multiple myeloma (immunoglobulin crystals), Waldenström disease, lymphoproliferative disorders with monoclonal gammopathy, chronic myeloid leukemia, myelodysplastic syndromes and atypical mycobacterial infection (Camou 2025); abundant pseudo-Gaucher cells delayed a myeloma diagnosis (Beaton 2018); thalassemia intermedia (Gajendra 2015); extranodal NK/T-cell lymphoma, with hemophagocytosis (Jeffrey 2023) Camou 2025; Beaton 2018; Gajendra 2015; Jeffrey 2023

Gaucher cells and enzyme confirmation. Gaucher cells infiltrate the marrow, spleen and liver and cause the cytopenias, organomegaly and bone lesions (Camou 2025). In one patient with hepatosplenomegaly, a double enzymatic assay separated Niemann-Pick disease from Gaucher disease after foamy histiocytes were seen in the marrow (Vélez Pinos 2023). Enzyme diagnosis and the biomarkers lyso-Gb1 and chitotriosidase are taught in Newborn Screening and Biochemical Genetics: Amino Acid, Organic Acid, Fatty Acid Oxidation, Urea Cycle, Lysosomal and Peroxisomal Disorders, and pseudo-Gaucher cells in chronic myeloid leukemia in Myeloproliferative Neoplasms: Chronic Myeloid Leukemia with Molecular Monitoring, Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis and Other Myeloproliferative Neoplasms.

Benign versus malignant lymphoid aggregates in marrow

Benign lymphoid aggregates are associated with infections, autoimmune disorders and medications, or are idiopathic (Maccio 2022). Aggregates were present in 5 of 38 (13.2%) normal control trephines and 34 of 140 (24.3%) MDS trephines, and CD20 and CD3 staining indicated polyclonality (Book 2022). In 128 marrows with benign aggregates and 78 with malignant B-cell aggregates, 5 features correlated with malignancy (Johnston 2015).

Feature favoring malignancy Odds ratio (95% CI) Source
Infiltrative edges 80.54 (31.76–204.21) Johnston 2015
B-cell pattern of B and T distribution 30.08 (13.28–68.10) Johnston 2015
Paratrabecular location 10.17 (3.96–26.12) Johnston 2015
Size >600 µm 6.83 (3.61–12.93) Johnston 2015

Cytologic atypia also correlated with malignancy. More than 2 of the 5 features were strongly predictive of malignancy (Johnston 2015).

Clonality testing. IGH and IGK rearrangement PCR detected clonality in 60% of B-cell lymphomas with marrow aggregates and in 15% of morphologically benign aggregates. During at least 2 years of follow-up, only 1 patient with a clonal, benign-appearing aggregate relapsed with lymphoma. Autoimmune and infectious conditions can produce clonal B-cell aggregates, so clonality results are interpreted with morphology and immunophenotype (Evans 2022). Lymphoma patterns in the marrow are taught in Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia.

Reactive plasmacytosis versus plasma cell neoplasm

In 146 published cases of reactive plasmacytosis in blood or marrow, infection caused 31% (viral infection 21%), angioimmunoblastic T-cell lymphoma 23%, drugs 19%, other malignancies 12% and autoimmune disease 6%. Plasma cell levels overlapped widely between categories (Munoz de Toro 2024). Reactive plasmacytosis in HIV infection and visceral leishmaniasis is described in Infections in Blood and Bone Marrow: Malaria, Babesiosis, Ehrlichiosis and Anaplasmosis, Other Blood Parasites, Histoplasma and Leishmania, Viral Infections and Marrow Granulomas.

Light chain restriction by flow cytometry, immunohistochemistry or in situ hybridization separates clonal from polyclonal plasma cells and is taught in Plasma Cell Neoplasms and Diseases with Paraproteins: MGUS, Smoldering and Plasma Cell Myeloma, Plasmacytoma, Plasma Cell Leukemia, Amyloidosis, POEMS Syndrome and Heavy Chain Diseases. Marrow granulomas are taught in Infections in Blood and Bone Marrow: Malaria, Babesiosis, Ehrlichiosis and Anaplasmosis, Other Blood Parasites, Histoplasma and Leishmania, Viral Infections and Marrow Granulomas.

Thymic hyperplasia: true, rebound, follicular and lymphoepithelial sialadenitis-like types

Type Clinical setting Histology and immunohistochemistry Source
True thymic hyperplasia Mainly infants and children, in whom the thymus can exceed 100 g; very rare in adults; no autoimmune association Enlarged gland above the age-adjusted weight limit with normal corticomedullary architecture, Hassall corpuscles, thin septa and no lymphoid follicles; TdT-positive, CD5-low cortical thymocytes and TdT-negative, CD5-high medullary thymocytes Porubsky 2025
Thymic parenchymal hyperplasia in adults and children 44 patients aged 7 months to 64 years (38 female); masses of 3.5–24 cm (median 10 cm); 29 first diagnosed as thymoma or thymoma versus hyperplasia Lobules with corticomedullary architecture and Hassall corpuscles separated by mature fat within a thin capsule; no follicular hyperplasia, atypia or confluent lobules; normal keratin-positive epithelial distribution with CD3, TdT and CD1a-positive lymphocytes Suster 2023
Rebound thymic hyperplasia Children and young adults after recovery from infection or after stopping immunosuppression, radiotherapy or chemotherapy; usually asymptomatic Preserved compartments with fewer Hassall corpuscles; weight usually <100 g Porubsky 2025
Thymic follicular hyperplasia Early-onset myasthenia gravis with anti-acetylcholine receptor antibodies Germinal centers within thymic lobes (CD20, CD23 or CD21; CD10 and BCL6 positive, BCL2 negative) with thinning of the TdT-positive cortex Porubsky 2025
Lymphoepithelial sialadenitis-like thymic hyperplasia Non-myasthenic autoimmune disease in 33% of patients; association with thymic MALT lymphoma Epithelial-lymphoid proliferation with architectural distortion and frequent cysts Porubsky 2025

Thymoma differential. Type B1 thymoma can have an organoid pattern resembling normal thymus. A fibrous capsule and septa with medullary islands lacking Hassall corpuscles support B1 thymoma (Porubsky 2025). Antibodies against titin, ryanodine receptor or MuSK are less common with follicular hyperplasia and raise suspicion of thymoma-associated or late-onset myasthenia gravis (Porubsky 2025). Thymic cytology is taught in Spleen and Thymus FNA and Pediatric Lymph Node Cytology and Thymoma and Thymic Carcinoma on FNA.

Infections in Blood and Bone Marrow: Malaria, Babesiosis, Ehrlichiosis and Anaplasmosis, Other Blood Parasites, Histoplasma and Leishmania, Viral Infections and Marrow Granulomas

Definition. Many infections are first recognized on a blood film or a marrow specimen. Blood parasites (Plasmodium, Babesia, trypanosomes and microfilariae), spirochetes, intracellular bacteria (Anaplasma and Ehrlichia) and intracellular yeasts or amastigotes (Histoplasma and Leishmania) are identified by their morphology, and the identification is confirmed by antigen, molecular, serologic or culture methods. EBV, HIV and parvovirus B19 produce characteristic blood and marrow changes. Granulomas in the marrow have infectious and noninfectious causes (Maccio 2023).

Related page: Microbiology Specimens, Stains, Culture Media and Blood Cultures (specimen collection, stains and blood cultures) Related page: Mycobacteria, Nocardia, Spirochetes, Mycoplasma, Chlamydia and Other Intracellular Bacteria (serology and PCR for Rickettsia, Ehrlichia, Anaplasma, Borrelia and Coxiella) Related page: Hemolytic Anemias: Red Cell Membrane and Enzyme Defects and Paroxysmal Nocturnal Hemoglobinuria (malaria-associated hemolysis) Related page: Blood Donor Eligibility, Collection and Donor Infectious Disease Testing (transfusion-transmitted malaria and babesiosis) Related page: Therapeutic Apheresis, ASFA Indications and Hematopoietic Progenitor Cell Products (red cell exchange for parasitemia) Related page: Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders (parvovirus B19 and pure red cell aplasia, and hemophagocytic lymphohistiocytosis) Related page: Lymph Node Pathology: Normal Structure, Triage, Reactive and Infectious Lymphadenopathy, Castleman and IgG4-Related Disease, and Metastases to Lymph Node and Marrow (infectious mononucleosis in the lymph node) Related page: Leukocyte Morphologic Anomalies, Dysplasia Mimics, Reactive Lymphocytes, and Body Fluid and CSF Cell Counts (reactive lymphocyte morphology) Related page: Reactive Bone Marrow Findings: Therapy Effects, Serous Atrophy, Necrosis, Bone Disease, Storage Cells, Lymphoid Aggregates, Reactive Plasmacytosis and Thymic Hyperplasia (gelatinous transformation, marrow necrosis and causes of reactive plasmacytosis) Related page: Large B-Cell Lymphomas, Burkitt Lymphoma, Immunodeficiency-Associated Lymphoproliferations, Hodgkin Lymphomas and Lymphoma Staging (HIV-associated lymphomas) Related page: Granulomatous Lymphadenitis (Cytology) (granulomatous lymphadenitis on FNA) Related page: Normal Hematopoiesis and Bone Marrow Examination: Procedure, Processing, Normal Findings, Cytochemistry and Reporting (marrow specimen allocation, including cultures in people with HIV)

Malaria: thick and thin films, staining and the examination standard

BCSH 2013 guideline. Thick and thin films are used routinely. Thick films are stained with Giemsa or Field stain, and thin films with Giemsa or Leishman stain. Two observers each examine at least 200 high-power fields on the thick film. A positive thick film is followed by species identification on the thin film. For Plasmodium falciparum and P. knowlesi, the percentage of parasitized red cells or the number of parasites per microliter is estimated and reported. Rapid diagnostic tests (RDTs) cannot replace microscopy and are a supplementary test where staff are relatively inexperienced. Malaria RDTs are negative in babesiosis (Bailey 2013).

Film preparation (CDC). Venous blood films are made as soon as possible, because delay changes parasite morphology and staining. At least 2 thick and 2 thin films are prepared. A thick film covers about 1.5 cm² and is thin enough for newsprint to be barely read through it when wet. It dries for at least 30 minutes and is not fixed with methanol or heat. The thin film has a feathered edge and is fixed in absolute methanol. Films from anticoagulated blood detach more easily during staining, and thick films are most affected (CDC 2026a). Giemsa stain shows Schüffner dots and Maurer clefts (CDC 2026b).

Examination. The thick film detects parasites and the thin film identifies the species (CDC 2026b). The thick film is scanned at 10× or 20× for microfilariae and then examined under oil immersion. WHO recommends screening at least 100 oil-immersion fields of about 20 white cells each before a thick film is reported as negative, which corresponds to a sensitivity of about 4 parasites/µL. NCCLS standards recommend at least 300 oil-immersion fields (CDC 2026c). Delayed processing produces compact or amoeboid forms, exflagellation and ookinetes (CDC 2026b).

Parasitemia calculation from thin and thick films

Film Method Formula Source
Thin film Parasitized red cells are counted among 500–2,000 red cells: 500 when parasitemia is high (>10%) and 2,000 or more when it is low (<1%). Asexual forms and gametocytes are counted separately % parasitemia = (parasitized red cells ÷ total red cells counted) × 100 CDC 2026c
Thick film Parasites are counted against white cells until 500 parasites or 1,000 white cells are reached, whichever comes first Parasites/µL = (parasites counted ÷ white cells counted) × patient white cell count per µL, or × 8,000/µL when the count is unknown CDC 2026c

Plasmodium species identification on the thin film

Feature P. falciparum P. vivax P. ovale P. malariae P. knowlesi
Infected red cell size Normal Rings normal to 1.25×; later stages enlarged 1.5–2×, may be distorted Normal to 1.25×, round to oval, some fimbriated Normal to 0.75× Normal to 0.75×
Stippling and clefts Maurer clefts under some staining conditions Fine Schüffner dots Schüffner dots Ziemann stippling, rarely Sinton and Mulligan stippling, rarely
Rings Delicate, about 1/5 of the red cell diameter, 1–2 chromatin dots; appliqué (accolé) forms Thick cytoplasm, large chromatin dot, sometimes pseudopods Sturdy cytoplasm, large chromatin Sturdy, thick cytoplasm; bird's-eye forms Delicate, 1–2 chromatin dots; appliqué and rectangular forms; mature rings may fill half the cell
Trophozoites Seldom seen in peripheral blood; compact cytoplasm, dark pigment Large and amoeboid with fine yellow-brown pigment; some band-like Compact with dark-brown pigment Compact; band and basket forms; coarse dark-brown pigment Band forms resembling P. malariae; coarse dark-brown pigment
Schizonts Seldom seen in peripheral blood except in severe infection; 8–24 merozoites 12–24 merozoites 6–14 merozoites 6–12 merozoites, often in rosettes; can be common in blood Up to 16 merozoites (average 10); rosettes
Gametocytes Crescent or sausage shaped, distorting the red cell Round to oval, almost filling the cell Round to oval, compact Round to oval, compact Round to oval, compact

All data in the table: CDC 2026b. Multiple infection of single red cells is more common in P. falciparum than in other species and is not uncommon in P. vivax, P. ovale and P. knowlesi (CDC 2026b).

P. knowlesi and P. malariae. In 1,569 confirmed P. knowlesi infections, the pooled rate of misidentification as P. malariae by microscopy was 57%, reaching 87% in Sarawak and 85% in Sabah. WHO recommends reporting microscopic P. malariae in P. knowlesi-endemic areas as P. malariae/P. knowlesi, and molecular testing of malariae-like parasites at high density could help identify P. knowlesi, particularly in nonendemic countries (Mahittikorn 2021).

Malaria antigen and molecular tests

Test Target and performance Source
RDT Histidine-rich protein 2 (HRP2, P. falciparum), Plasmodium aldolase and Plasmodium lactate dehydrogenase (pLDH); 1 RDT is licensed in the United States CDC 2026b
HRP2 persistence after treatment After artesunate-amodiaquine treatment of uncomplicated P. falciparum malaria, HRP2 had a terminal half-life of about 9 days after parasite clearance and remained detectable for up to 28 days, so HRP2-based RDTs can stay positive for weeks after cure Lamsfus Calle 2024
HRP2 gene deletions pfhrp2 and pfhrp3 deletions cause false-negative HRP2-based RDTs; reported rates range from 2.4% to 57.8% (57.8% in southern Ethiopia); RDT performance declines where deletion prevalence exceeds the WHO threshold of 5% S R S 2026
Real-time PCR Species-specific; detects parasites below the microscopic threshold; nested PCR for suspected mixed infection CDC 2026b
Automated hematology analyzer (Sysmex) Pooled sensitivity 95% and specificity 99% in a meta-analysis of 15 studies (Mulatie 2024). The dedicated XN-31 analyzer had 100% sensitivity and 99.46% specificity against expert microscopy in 310 adults and flagged P. falciparum correctly in 116 of 117 cases, but labeled 5 P. falciparum infections as other species (Onsongo 2025) Mulatie 2024; Onsongo 2025
Antibody (IFA) Not used for acute diagnosis; used to screen donors in transfusion-transmitted cases and for recently treated patients whose diagnosis is questioned; cross-reacts with Babesia CDC 2026b

Babesiosis: smear morphology, IDSA 2020 diagnosis and distinction from P. falciparum

IDSA 2020 diagnostic recommendations. Babesiosis is confirmed by peripheral blood smear examination or PCR in a patient with epidemiologic risk and compatible clinical findings, and antibody testing is not used for this purpose (strong recommendation, moderate-quality evidence). A positive antibody test is confirmed by smear or PCR before treatment, because antibodies persist for a year or more after the infection clears. Parasitemia is monitored by smears during acute illness. Immunocompetent patients are not retested once symptoms resolve, and immunocompromised patients are monitored until smears are negative, with PCR if symptoms persist with negative smears (Krause 2021). Exchange transfusion is suggested for selected patients with severe babesiosis, including parasitemia above 10% (weak recommendation, low-quality evidence) (Krause 2021).

Species. Babesia microti, B. duncani and B. divergens cause human infection in the United States; B. divergens, B. microti and B. venatorum in Europe; and B. venatorum, B. microti and a B. crassa-like pathogen in Asia (Krause 2021). B. microti is the agent most often identified in the United States (Northeast and Midwest) and also infects people who have a spleen. B. divergens causes most European cases, usually in splenectomized patients, and tends to be more severe. Morphology does not identify the species (CDC 2026d).

Serology. Indirect immunofluorescence with B. microti antigen detects antibodies in 88%–96% of patients with B. microti infection, and titers reach 1:1,024 or more in the first weeks. Cross-reactions with malaria occur. A negative B. microti test after West Coast exposure can be falsely negative, and B. duncani antibodies are tested (CDC 2026d). PCR is used when smears do not separate Babesia from Plasmodium and to identify the species, and repeated smears may be needed (CDC 2026d).

Feature Babesia P. falciparum Source
Rings Pleomorphic, sometimes vacuolated; resemble P. falciparum rings Delicate, 1–2 chromatin dots, appliqué forms CDC 2026b; CDC 2026d
Tetrads Dividing forms characteristic of Babesia Absent CDC 2026d
Pigment None Pigmented CDC 2026b; CDC 2026d
Sexual forms Male and female gametes not distinguishable by light microscopy Crescent or sausage-shaped gametocytes CDC 2026b; CDC 2026d
Malaria RDT Negative HRP2 positive unless pfhrp2 is deleted Bailey 2013; S R S 2026

Extracellular clumped forms also indicate Babesia (CDC 2026d).

Ehrlichia and Anaplasma morulae on blood films

Morulae are intracytoplasmic clusters of ehrlichiae or anaplasmae within circulating leukocytes. They are seen during the first week of illness and are highly suggestive of infection. Morulae are a presumptive clue, and their visualization requires confirmatory diagnostic testing (Biggs 2016).

Organism Cell with morulae Vector Blood and marrow findings Source
Ehrlichia chaffeensis Monocytes; occasionally in CSF or marrow Amblyomma americanum (lone star tick) Leukopenia (nadir usually 1,300–4,000/µL); thrombocytopenia (nadir usually 50,000–140,000/µL, occasionally <20,000/µL); later anemia in 50%; normocellular or hypercellular marrow in pancytopenia Biggs 2016
Anaplasma phagocytophilum Granulocytes Ixodes scapularis in the northeastern and midwestern United States; Ixodes pacificus on the West Coast Thrombocytopenia, leukopenia, increased immature neutrophils and mild anemia; normocellular or hypercellular marrow, in which morulae may be seen Biggs 2016

Ehrlichia ewingii morulae occur in granulocytes in blood, marrow or CSF (Biggs 2016).

Limitations of smear examination. Blood smear examination is relatively insensitive and inconsistent. Morulae are distinguished from overlying platelets, Döhle bodies, phagocytosed bacteria and toxic granulation by experienced microscopists. A concentrated buffy coat smear can improve the yield. Smears are not useful for Rocky Mountain spotted fever, other spotted fever rickettsioses or the EML agent (Biggs 2016). Serology and whole-blood PCR are taught in Mycobacteria, Nocardia, Spirochetes, Mycoplasma, Chlamydia and Other Intracellular Bacteria.

Relapsing fever borreliae, Bartonella bacilliformis, trypanosomes and microfilariae in blood

Relapsing fever Borrelia. Spirochetes in Giemsa-stained thick blood films from febrile patients are the reference method for relapsing fever borreliae. Dark-field microscopy shows them best, and Wright-Giemsa and acridine orange stains also detect them. Fewer spirochetes circulate during later febrile episodes. Smears lack sensitivity and cannot identify the species. Real-time PCR for the flagellin gene (flaB) detects as few as 10 borreliae/mL. B. recurrentis is louse-borne, and the other African relapsing fever species are tick-borne (Fotso Fotso 2015). B. miyamotoi is taught in Mycobacteria, Nocardia, Spirochetes, Mycoplasma, Chlamydia and Other Intracellular Bacteria.

Bartonella bacilliformis (Carrión disease). B. bacilliformis first infects erythrocytes and then endothelial cells (Jimenez-Vasquez 2023). Bartonellosis affects Andean communities in Peru, Colombia and Ecuador. In 191 cases from a Peruvian outbreak, 65% of patients were 14 years old or younger, and the sensitivity of the blood smear against blood culture in acute disease was 25% (Sanchez Clemente 2016).

Organism Blood morphology Diagnostic setting Source
Trypanosoma cruzi (Chagas disease) C-shaped trypomastigotes on fixed Giemsa films; 12–30 µm; large subterminal or terminal kinetoplast, central nucleus, undulating membrane and flagellum. Tissue amastigotes resemble Leishmania Acute phase: trypomastigotes on films and motile forms in fresh blood; PCR for suspected transfusion or transplant transmission. Chronic phase: rare parasites; 2 serologic tests (EIA and TESA) with IFA as tie-breaker CDC 2026e
Trypanosoma brucei gambiense and T. b. rhodesiense (African trypanosomiasis) Trypomastigotes 14–33 µm with a small posterior kinetoplast, central nucleus, undulating membrane and free anterior flagellum; subspecies identical Chancre fluid, lymph node aspirate, blood, marrow and CSF in late disease; buffy coat, mini anion-exchange or QBC concentration; card agglutination screening for gambiense; no validated nucleic acid test CDC 2026f
Wuchereria bancrofti Sheathed; 240–300 µm on stained films; tail nuclei do not reach the tip Nocturnal periodicity; night blood; circulating antigen tests at any time of day CDC 2026g
Brugia malayi Sheathed; 175–230 µm; gap between terminal and subterminal tail nuclei Nocturnal periodicity; Southeast Asia CDC 2026g
Brugia timori Sheathed; sheath does not stain with Giemsa; about 310 µm Lesser Sunda Islands of Indonesia CDC 2026g
Loa loa Sheathed; 230–250 µm on stained films; tapered tail with nuclei to the tip Diurnal periodicity; blood drawn between 10 AM and 2 PM; Africa; adult worms in the subconjunctiva; Calabar swellings CDC 2026h
Mansonella perstans Unsheathed; 190–200 µm; blunt tail with nuclei to the tip Blood; nonperiodic; Africa and parts of Central and South America CDC 2026i
Mansonella ozzardi Unsheathed; 160–205 µm; pointed, hooked tail with nuclei ending before the tip Blood; nonperiodic; Central and South America and the Caribbean CDC 2026i
Mansonella streptocerca Unsheathed; hooked tail with nuclei to the end Skin; West and Central Africa CDC 2026i

Microfilaria concentration. In the Knott technique, 1 mL of EDTA venous blood is mixed with 2% formaldehyde (9 parts to 1 part blood) and centrifuged at 500 × g for 10 minutes. Filtration through a Millipore or Nuclepore membrane filter with 5-µm pores is an alternative. Fingerstick blood is preferred, because microfilariae concentrate in peripheral capillaries (CDC 2026a).

Histoplasma, Talaromyces, Cryptococcus and Leishmania in blood and bone marrow

Histoplasma capsulatum. H. capsulatum is a dimorphic fungus that grows as a mold at room temperature and as a yeast at 37 °C. In disseminated histoplasmosis the blood film can show yeast-like cytoplasmic inclusions in neutrophils. Marrow aspirate stains (Grocott, Giemsa and PAS with diastase) show the yeasts, and culture at 30 °C and 37 °C isolates the fungus (Pallarés 2026). In a marrow series, Histoplasma yeasts were identified by an eccentric nucleus and a thick cell wall (Maharjan 2026). Fungal stains and culture are taught in Microbiology Specimens, Stains, Culture Media and Blood Cultures.

Talaromyces marneffei. Giemsa, Grocott methenamine silver and Wright stains show round or oval intracellular or extracellular yeasts 2–3 µm in diameter with a central septation, which allows a presumptive diagnosis. Peripheral blood microscopy is occasionally positive with high fungemia. Definitive diagnosis rests on culture from blood, skin, marrow, lymph node or respiratory specimens (Brown 2026).

Cryptococcus. On marrow aspirate smears, Cryptococcus yeasts are identified by a thick capsule. In trephine sections, refractile yeasts are surrounded by cystic spaces and are highlighted by silver methenamine stain (Maharjan 2026).

Leishmania (visceral leishmaniasis). Visceral leishmaniasis is caused by the L. donovani complex (L. donovani, L. infantum and L. chagasi) (CDC 2026j). Amastigotes (Leishman-Donovan bodies) are round to oval, 2–4 µm, aflagellate and contain a nucleus and a kinetoplast (Mangat 2026). They are found within macrophages and are indistinguishable from T. cruzi amastigotes (CDC 2026j). Parasite density on marrow aspirates is graded by the Chulay-Bryceson system from 1+ (1–10 bodies per 1,000 oil-immersion fields) to 5+ (10–100 bodies per field) (Mangat 2026).

Marrow finding in 42 patients with visceral leishmaniasis Frequency Source
Plasmacytosis 88.0% Mangat 2026
Hypercellularity 81.0% Mangat 2026
Increased histiocytes 80.9% Mangat 2026
Hemophagocytosis 52.4% Mangat 2026
Increased eosinophil precursors 42.9% Mangat 2026
Dyserythropoiesis 38.1% Mangat 2026
Myelofibrosis 14.2% Mangat 2026

Pancytopenia was present in 73.8%, and higher parasite density correlated with splenomegaly, pancytopenia and plasmacytosis (Mangat 2026). For the diagnosis of visceral leishmaniasis, marrow is classically aspirated from the sternum in adults and the iliac crest in children (Siala 2022). Leishmania serology can cross-react with T. cruzi (CDC 2026j).

Test for visceral leishmaniasis Performance Source
Marrow aspirate microscopy Reference method; sensitivity 53%–86% Siala 2022
Splenic aspirate microscopy Sensitivity 93%–99% Siala 2022
Marrow culture (NNN biphasic medium) Sensitivity 60%–100% Siala 2022; CDC 2026j
rK39 RDT Sensitivity 97% in the Indian subcontinent, 88%–94% in Brazil and 85% in East Africa; specificity >90% Siala 2022
PCR (ITS2 with sequencing) Species identification within days CDC 2026j

Parvovirus B19, infectious mononucleosis and HIV: blood and marrow changes

Parvovirus B19. Giant pronormoblasts, pure red cell aplasia and their confirmation are taught in Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders. In people with HIV, parvovirus B19 causes pure red cell aplasia, and zidovudine, lamivudine and emtricitabine can cause a reversible pure red cell aplasia that mimics it (Opie 2024).

Infectious mononucleosis: blood findings. Initial testing is a blood count with differential, for >40% lymphocytes and >10% atypical lymphocytes, and a rapid heterophile antibody test (Sylvester 2023). In 181 heterophile-positive outpatients, lymphocytosis ≥50% had a sensitivity of 66.3% and specificity of 84.5%, and atypical lymphocytes ≥10% of white cells had a sensitivity of 74.6% and specificity of 92.3%. Smudge cells and cloverleaf lymphocyte nuclei had high specificity and low sensitivity. Analyzer flags marked 86.2% of heterophile-positive samples for review (Brigden 1999). Among 168 patients older than 14 years with serologically confirmed infectious mononucleosis, EBV caused 72.6% and cytomegalovirus 27.4%. Patients with cytomegalovirus mononucleosis were a median of 10 years older, and atypical lymphocytosis, lymphadenopathy, tonsillar white coating, hepatosplenomegaly and a short interval from onset to presentation predicted EBV (Ishii 2019). Thrombocytopenia and absolute neutropenia each occurred in 14% (7 of 51) of patients with acute Epstein-Barr virus (EBV) infectious mononucleosis (Naughton 2025).

Heterophile antibody test. Sensitivity is 87% and specificity 91%, and false-negative results occur during the first week of illness. EBV viral capsid antigen (VCA) antibody testing is more sensitive and specific (Sylvester 2023). Low sensitivity in children younger than 5 years is taught in Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders.

EBV serologic pattern Interpretation Source
VCA IgM and VCA IgG without EBNA-1 IgG Acute infection De Paschale 2012
VCA IgG and EBNA-1 IgG without VCA IgM Past infection De Paschale 2012
VCA IgG alone Acute or past infection De Paschale 2012
VCA IgM, VCA IgG and EBNA-1 IgG together Recent infection or reactivation De Paschale 2012
Isolated EBNA-1 IgG Doubtful pattern De Paschale 2012

Ambiguous patterns are resolved with IgG avidity, immunoblot, heterophile antibodies, early antigen (EA-D) antibodies or EBV DNA (De Paschale 2012). Lymph node histology in infectious mononucleosis is taught in Lymph Node Pathology: Normal Structure, Triage, Reactive and Infectious Lymphadenopathy, Castleman and IgG4-Related Disease, and Metastases to Lymph Node and Marrow, and reactive lymphocyte morphology in Leukocyte Morphologic Anomalies, Dysplasia Mimics, Reactive Lymphocytes, and Body Fluid and CSF Cell Counts.

HIV infection. Cytopenias are the most frequent hematologic abnormality in people with HIV. They increase with lower CD4 counts, and antiretroviral therapy reduces the prevalence of anemia by about 45% after 1 year. Dysplasia of 1 or more cell lines in the blood and marrow is frequent in advanced disease and is associated with cytopenias (Opie 2024). Other causes include anemia of chronic disease with raised IL-6 and hepcidin, autoimmune hemolytic anemia, HIV-associated immune thrombocytopenia and thrombotic thrombocytopenic purpura (Opie 2024).

HIV marrow finding Detail Source
Opportunistic infection M. tuberculosis is the most common marrow coinfection; Mycobacterium avium complex, Cryptococcus neoformans and H. capsulatum are rarer Opie 2024
Hypocellularity and granulomas Each in 37.8% of trephines in one series; most diagnoses infectious Soto-Avila 2026
Cytomegalovirus Marrow aspirate PCR positive in 2 of 3 patients tested Soto-Avila 2026
Gelatinous transformation Reported in 22 of 75 patients with HIV in one series; morphology in Reactive Bone Marrow Findings: Therapy Effects, Serous Atrophy, Necrosis, Bone Disease, Storage Cells, Lymphoid Aggregates, Reactive Plasmacytosis and Thymic Hyperplasia Shergill 2017
Reactive plasmacytosis Common; myeloma occurs at a younger age in people with HIV Opie 2024
Lymphoma Diffuse large B-cell lymphoma is the most common HIV-associated lymphoma, followed by Burkitt lymphoma, Hodgkin lymphoma and plasmablastic lymphoma; Hodgkin lymphoma frequently involves the marrow Opie 2024

Bone marrow granulomas: causes, fibrin-ring granulomas and stains

Marrow granulomas are rare and usually incidental. Causes are infectious (most often tuberculous and nontuberculous mycobacteria, and other bacteria, viruses, fungi and parasites) and noninfectious (drugs, autoimmune disease, sarcoidosis and hematologic and nonhematologic malignancies). Necrotizing granulomas suggest infection, with tuberculosis the most common cause. Cases suspicious for infection are studied with Ziehl-Neelsen staining or molecular tests, and untargeted metagenomics is used when no cause is found (Maccio 2023).

Series or finding Result Source
Frequency 0.3%–3% of marrow biopsies; 110 of 11,339 (0.97%) in a high-tuberculosis setting Wang 2018
Causes in a high-tuberculosis setting Infection 64.5%, malignancy 4.5%, autoimmune disease 3.6%, no cause 27.3%; tuberculosis in 62 of 71 infectious cases (87.3%) Wang 2018
Non-tuberculous infections in a high-tuberculosis setting Fungal infection 4, typhoid or paratyphoid fever 3 and brucellosis 2 of 71 infectious cases Wang 2018
Advanced HIV infection Granulomas are not specific for tuberculosis and occur with fungal and other infections Soto-Avila 2026
Fibrin-ring granuloma Epithelioid granuloma with a central fat vacuole and a peripheral fibrinoid ring Chung 2007
Causes of fibrin-ring granulomas Coxiella burnetii (Q fever), EBV, CMV, hepatitis A virus, allopurinol-induced hepatitis, Hodgkin lymphoma and peripheral T-cell lymphoma Chung 2007
EBV and fibrin-ring granulomas EBV was the most common proven cause (17 of 40 cases, 43%); survival was shorter with EBV (median 3.0 vs 11.8 months) Chung 2010
Q fever Doughnut (fibrin-ring) granulomas are highly specific for Q fever without being pathognomonic Carvalho 2021

malaria parasitemia calculator for thin and thick blood films

Leukocyte Morphologic Anomalies, Dysplasia Mimics, Reactive Lymphocytes, and Body Fluid and CSF Cell Counts

Definition. Leukocyte morphologic anomalies are inherited or acquired changes in nuclear segmentation, granules or cytoplasm of blood leukocytes. Inherited anomalies indicate mucopolysaccharidosis (Alder-Reilly anomaly), neutral lipid storage disease (Jordans anomaly), granule defects (Chédiak-Higashi syndrome, specific granule deficiency) or LBR and MYH9 variants. Acquired pseudo-Pelger-Huët change occurs with medications, infection and inflammation and is reversible. Marrow findings and the proportion of affected neutrophils separate it from the change in myelodysplastic neoplasms (MDS) (Wang 2011). Body fluid cell counts quantify nucleated cells and red cells in serous, cerebrospinal, synovial and dialysis fluids by hemocytometer or by analyzer body fluid modes (Cho 2020).

Related page: Automated Blood Counts, Reticulocyte Count and Peripheral Smear Review (Pelger-Huët anomaly, Chédiak-Higashi syndrome, MYH9-related inclusions, toxic changes, ICSH lymphocyte terms and smudge cells) Related page: Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders (neutropenia, leukocytosis, lymphocytosis, monocytosis, basophilia, eosinophilia, neutrophil function disorders and HLH) Related page: Myelodysplastic Neoplasms: WHO 5th Edition and ICC Types, Dysplasia Morphology, TP53-Mutated Myeloid Neoplasms and Prognostic Scoring (dysplasia criteria and reactive mimics of MDS) Related page: CSF Specimen Handling and Normal and Contaminant Findings (CSF handling, chamber counts, age-specific reference values, neonatal correction ratios and erythrophages) Related page: Special Non-Neoplastic Effusions and Pediatric and Pericardial Fluid Cytology (eosinophilic pleural effusion and peritoneal dialysis effluent cytology) Related page: Synovial fluid cell counts and cytology: septic, rheumatoid and traumatic effusions (synovial fluid cell count categories and septic arthritis) Related page: Inherited Thrombocytopenias, Inherited and Acquired Platelet Function Disorders, and Reactive Versus Clonal Thrombocytosis (MYH9-related disease and other inherited thrombocytopenias) Related page: Mastocytosis, Hypereosinophilic Syndrome and Myeloid/Lymphoid Neoplasms with Tyrosine Kinase Fusions, Chronic Myelomonocytic Leukemia and Other MDS/MPN (clonal eosinophilia, hypereosinophilic syndrome and mast cell disease) Related page: Histiocytic and Dendritic Cell Neoplasms, Hemophagocytic Lymphohistiocytosis in Tissue and Pathology of the Spleen (hemophagocytic lymphohistiocytosis in tissue)

Inherited leukocyte anomalies

Anomaly Cells affected and morphology Genetic basis and associations Source or related page
Pelger-Huët anomaly Hyposegmented neutrophils with condensed chromatin Heterozygous LBR variants Automated Blood Counts, Reticulocyte Count and Peripheral Smear Review
Chédiak-Higashi syndrome Giant cytoplasmic granules in granulocytes LYST; autosomal recessive Automated Blood Counts, Reticulocyte Count and Peripheral Smear Review
MYH9-related disease Döhle-like neutrophil inclusions with giant platelets MYH9; autosomal dominant Automated Blood Counts, Reticulocyte Count and Peripheral Smear Review; Inherited Thrombocytopenias, Inherited and Acquired Platelet Function Disorders, and Reactive Versus Clonal Thrombocytosis
Alder-Reilly anomaly Aberrant leukocyte granulation; analyzer flags can prompt the smear review that detects it Impaired glycosaminoglycan degradation in mucopolysaccharidosis, including MPS VII (GUSB, β-glucuronidase deficiency) Roemer 2026
Jordans anomaly Multiple lipid vacuoles in neutrophils, eosinophils and basophils, and in platelets in a reported case Neutral lipid storage disease: Chanarin-Dorfman syndrome (ABHD5/CGI-58; ichthyosis, elevated transaminases) or neutral lipid storage disease with myopathy (adipose triglyceride lipase, ATGL) Sánchez-Cortés 2025
Specific granule deficiency Hypogranular neutrophils with atypical bilobed nuclei; reduced granules; absent lactoferrin CEBPE (biallelic, or a dominant heterozygous missense variant) or biallelic SMARCD2; recurrent infections and abscesses of airways and skin Serwas 2018
  • Jordans anomaly staining. Sudan III vital staining confirms that the vacuoles contain lipid, and glycogen is absent (Sánchez-Cortés 2025).
  • Specific granule deficiency as an MDS mimic. Hypogranularity resembles myelodysplasia. C/EBPε is required for neutrophil differentiation beyond the promyelocyte stage and regulates secondary and tertiary granule proteins and nuclear segmentation. NADPH oxidase activity after zymosan stimulation is reduced. Neutrophils lack secondary and tertiary granule proteins such as lactoferrin, and the heterozygous CEBPE p.Val218Ala variant prevents nuclear localization of C/EBPε (Serwas 2018). Laboratory evaluation of neutrophil function disorders is covered in Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders.

Acquired pseudo-Pelger-Huët change and other dysplasia mimics

Acquired pseudo-Pelger-Huët change occurs in MDS and acute myeloid leukemia and also in severe infection, nutritional deficiency, autoimmune disease and with medications (Kurucu 2026). Other reactive causes of dysplasia, including copper deficiency, vitamin B12 deficiency, HIV and growth factor therapy, are tabulated in Myelodysplastic Neoplasms: WHO 5th Edition and ICC Types, Dysplasia Morphology, TP53-Mutated Myeloid Neoplasms and Prognostic Scoring.

Setting Neutrophil findings Distinguishing points Source
Medications after transplantation (mycophenolate mofetil, tacrolimus) Nuclear hypolobulation with abnormal chromatin clumping Reversible after the drug is stopped or reduced; with mycophenolate, the change preceded neutropenia and was presumably related to inhibition of guanosine nucleoside synthesis Banerjee 2000; Etzell 2006
Iatrogenic pseudo-Pelger change, series of 13 patients (marrow or stem cell transplantation 5, solid organ transplantation 3, CLL 3, autoimmune disease 1, breast carcinoma 1) Mean 47.4% of circulating neutrophils affected Normalization of segmentation in all 12 patients with follow-up; marrow usually lacks MDS features Wang 2011
MDS-related pseudo-Pelger change, 9 patients Mean 12.3% of circulating neutrophils affected At least 2 of hypercellularity (8 of 9), morphologic dysplasia (8 of 9), a clonal cytogenetic abnormality (7 of 9) and increased blasts (3 of 9) Wang 2011
Pediatric celiac disease Pseudo-Pelger change (≥5% threshold) in 87.1% versus 8.1% of controls; neutrophil dysplasia in 52.9% versus 1.4% Blood counts largely preserved; vitamin B12 and folate levels similar to controls Kurucu 2026
Valproic acid, 1 case Pseudo-Pelger-Huët cells with pancytopenia; megakaryocytic dysplasia in the marrow Cytogenetic and molecular studies negative for MDS-associated mutations; counts improved within a week of stopping the drug and normalized over the following weeks Ugwu 2026
Pegfilgrastim after nab-paclitaxel, 1 case Hyposegmentation, hypersegmentation (8–9 lobes), detached nuclear fragments, pseudo-Pelger-Huët cells, toxic granulation, clumped chromatin and asynchronous maturation; giant platelets Analyzer scattergram flagged the sample; the changes were absent on the fourth hospital day; detached nuclear fragments are characteristic of G-CSF-induced neutrophil dysplasia Tan 2025
COVID-19 Hyposegmented nuclei, toxic or decreased granulation with basophilic areas, left shift, apoptotic cells Accompanied by heterogeneous reactive lymphocytes and vacuolated monocytes Zini 2023

Diagnostic principle. Isolated pseudo-Pelger-Huët change is regarded as transient or benign unless MDS is proven (Wang 2011). Tacrolimus and mycophenolate given together produced the change, which resolved after the mycophenolate dose was reduced and did not recur when mycophenolate was increased after tacrolimus was stopped (Etzell 2006).

Reactive lymphocyte morphology

The ICSH terms "reactive lymphocyte" and "abnormal lymphocyte" are defined in Automated Blood Counts, Reticulocyte Count and Peripheral Smear Review. The CD8-positive T-cell nature of the reactive lymphocytes of infectious mononucleosis and the workup of lymphocytosis are covered in Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders.

Downey type Morphology Source
Type I Smaller cells with round, reniform or lobated nuclei, visible nucleoli, and basophilic, foamy or vacuolated cytoplasm Placek 2024
Type II Large cells with loosely clumped chromatin and abundant pale cytoplasm with radial basophilia at the edges, indented by adjacent red cells; the classic cell of infectious mononucleosis Placek 2024
Type III Medium to large pleomorphic "lymphoma-like" cells with irregular nuclei, moderately coarse chromatin, prominent nucleoli and deeply basophilic cytoplasm Placek 2024
  • Heterogeneity as the reactive clue. Reactive lymphocytosis shows a spectrum of small, reactive and lymphoma-like cells, whereas lymphoma cells are generally monomorphous. Simultaneous expansion of lymphocytes and monocytes supports a reactive process, and flow cytometry of lymphocyte subsets excludes a clonal disorder quickly (Placek 2024).
  • Transient stress lymphocytosis. Lymphocytosis with small, reactive or large granular lymphocytes follows cardiac emergencies, trauma, seizures, sickle cell vaso-occlusive crisis, acute drug toxicity, anaphylaxis and other acute illnesses. A single Downey type III cell viewed in isolation can be misread as circulating lymphoma (Placek 2024). Transient stress lymphocytosis usually resolves within 48 hours (Placek 2024).
  • Large granular and plasmacytoid lymphocytes. In COVID-19, large lymphocytes with pale or intensely blue cytoplasm, plasmacytoid lymphocytes with Mott cell-like inclusions, and increased large granular lymphocytes without atypia were reported in almost all morphologic studies (Zini 2023).
  • Pertussis. Absolute lymphocytosis in pertussis results from pertussis toxin-mediated inhibition of lymphocyte migration from blood into lymphoid tissue. Cleaved or lobulated lymphocytes with indented nuclei have been reported, and they decreased as the infection resolved (Ansari 2025).
  • Neoplastic lymphocytes. Smudge cells are covered in Automated Blood Counts, Reticulocyte Count and Peripheral Smear Review, CLL, prolymphocytes and hairy cells in Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia, and Sézary cells and T-cell large granular lymphocytic leukemia in Mature T-Cell and NK-Cell Neoplasms: Nodal, Leukemic, Extranodal and Cutaneous T-Cell Lymphomas.

Body fluid cell counting methods

  • Manual hemocytometer counts. Manual counting in a hemocytometer chamber has long been regarded as the reference method. It is time-consuming and subject to high interobserver variability. In one protocol, nucleated cells and red cells in non-CSF fluids were counted undiluted and unstained in a Neubauer chamber, and CSF nucleated cells were counted after 1:10 dilution in Türk solution (crystal violet and glacial acetic acid) (Cho 2020).
  • Cytocentrifuge differential. Wright-Giemsa-stained cytocentrifuge preparations are counted for at least 100 cells. Neutrophils, eosinophils and basophils are grouped as polymorphonuclear cells, and lymphocytes, plasma cells and monocytes as mononuclear cells. Macrophages, mesothelial cells and malignant cells are counted separately (Cho 2020).
  • Verification of analyzer body fluid modes. The ICSH 2014 guideline sets out the verification and performance assessment of automated cell counters for body fluids (Bourner 2014). The CLSI H56-A guideline covers collection, preservation, transport and analysis of body fluid samples (Saini 2025). Verification studies measure precision, linearity and the limits of blank, detection and quantification (Cho 2020).

Analyzer body fluid modes

Analyzer Total nucleated cell limit of quantification Notes Source
Beckman Coulter UniCel DxH 800 0.037 × 10⁹/L (37/µL) Red cell count in CSF did not agree acceptably with manual counting Cho 2020
Sysmex XN-350 (body fluid mode) 0.027 × 10⁹/L (27/µL) Fluorescence flow cytometry for nucleated cells; high-fluorescence body fluid cells (macrophages, mesothelial cells, atypical and malignant cells) fall outside the white cell scattergram Cho 2020
Sysmex UF-5000 0.025 × 10⁹/L (25/µL) Manufacturer-claimed analytical measurement range 0.001–10.000 × 10⁹/L for nucleated cells Cho 2020
  • Agreement with manual counts. In 542 fluids, all three analyzers agreed with manual nucleated cell and red cell counts, except the DxH 800 red cell count in CSF. Polymorphonuclear and mononuclear percentages agreed to varying degrees (Cho 2020).
  • Low CSF counts. The lower limits of automated CSF counts and confirmation of low counts in a chamber are covered in CSF Specimen Handling and Normal and Contaminant Findings.

Reference values and diagnostic thresholds for body fluid counts

Fluid Normal or diagnostic value Differential Source or related page
Normal pleural fluid (pleural lavage in healthy nonsmokers) About 1,716 × 10³ white cells/mL (about 1,700/µL); volume 0.26 mL/kg Macrophages 75%, lymphocytes 23%, mesothelial cells 1%, neutrophils 0%, eosinophils 0%; smokers had slightly more neutrophils Noppen 2000
Normal pericardial fluid (open heart surgery, 30 patients) Mean 1,430 leukocytes/µL Lymphocytes 53.2%, monocytes 11.6%; LDH 2.4 times and protein 0.6 times the serum level Ben-Horin 2005
Ascitic fluid in cirrhosis Polymorphonuclear count ≥250 cells/mm³ diagnoses spontaneous bacterial peritonitis (AASLD threshold, as reported by Haddadin 2025) Neutrophils Haddadin 2025
Peritoneal dialysis effluent White cells >100/µL (>0.1 × 10⁹/L) after a dwell of at least 2 hours, with >50% polymorphonuclear cells Neutrophils Li 2016
Pleural fluid eosinophilia ≥10% eosinophils Eosinophils Special Non-Neoplastic Effusions and Pediatric and Pericardial Fluid Cytology
  • Pericardial lymphocytosis. Because normal pericardial fluid is lymphocyte predominant with high LDH and protein, pleural-fluid criteria for transudates and exudates probably do not apply, and lymphocytosis is interpreted with caution (Ben-Horin 2005).
  • Spontaneous bacterial peritonitis threshold. The ≥250 cells/mm³ polymorphonuclear threshold was chosen for high sensitivity, and presumed spontaneous bacterial peritonitis is treated as soon as paracentesis shows it. Some studies have reported outcomes below the cutoff similar to those above it. An ascitic polymorphonuclear count <250 cells/mm³ with a positive ascitic culture is bacterascites (Haddadin 2025).

Peritoneal dialysis peritonitis (ISPD 2022; criteria unchanged from 2016)

  • Diagnostic criteria. Peritonitis is diagnosed when at least 2 of the following are present: abdominal pain and/or cloudy effluent; effluent white cell count >100/µL after a dwell of at least 2 hours with >50% polymorphonuclear cells; and a positive effluent culture (Li 2016). The 2022 update retains these criteria (Zheng 2026).
  • Cloudy effluent. Patients with cloudy effluent are treated as having peritonitis until it is excluded (Li 2016). Eosinophilic peritonitis as a noninfectious cause and the ISPD 2022 definitions of refractory and relapsing peritonitis are taught in Special Non-Neoplastic Effusions and Pediatric and Pericardial Fluid Cytology.
  • Automated peritoneal dialysis (ISPD 2016). The effluent white cell count depends on dwell length. With rapid-cycle automated peritoneal dialysis, the polymorphonuclear percentage is used, and more than 50% polymorphonuclear cells is strong evidence of peritonitis even when the white cell count is below 100/µL. Patients without a daytime dwell who present with daytime pain receive 1 L of dialysate for a 1- to 2-hour dwell before sampling (Li 2016).

CSF hematology

CSF handling, cell loss after collection, age-specific reference values, neonatal correction ratios and erythrophage timing are covered in CSF Specimen Handling and Normal and Contaminant Findings. Traumatic punctures that contain blasts are classified in Leukemia, Lymphoma and Plasma Cell Neoplasms in CSF.

Correction of CSF white cell counts after a traumatic puncture

  • Formula using peripheral counts. Corrected CSF WBC = CSF WBC − (CSF RBC × peripheral WBC ÷ peripheral RBC), with all counts in the same units (Lyons 2017).
  • Fixed correction factors. When peripheral counts are normal, 1 white cell is subtracted for every 500 to 1,500 red cells (Zhou 2024).
  • Performance in adults. In 195 adults with a traumatic puncture and tube 1 pleocytosis, tube 4 showed that 54% had false pleocytosis. These patients had bloodier CSF and milder pleocytosis. Specificity of the correction factors ranged from 29.2% to 71.7% and sensitivity from 84.3% to 97.8%. The 1:500 factor had the highest specificity, and the 1:1,500 factor the highest sensitivity. A corrected count that suggests only mild pleocytosis is interpreted cautiously (Zhou 2024).
  • Performance in infants. In 2,880 traumatic punctures in infants aged 60 days or younger, correction with a derived ratio lowered the sensitivity of CSF pleocytosis for bacterial meningitis from 88% to 67% and reduced the proportion of infants with pleocytosis from 78% to 33% (Lyons 2017). The derived neonatal correction ratio is taught in CSF Specimen Handling and Normal and Contaminant Findings.

Xanthochromia

  • Origin. After subarachnoid bleeding, red cells release hemoglobin that oxidizes to oxyhemoglobin, which is degraded over hours to bilirubin, producing yellow CSF (Sjulstad 2025).
  • Timing. CSF xanthochromia testing is the test of choice when the CT is negative and lumbar puncture is performed 12 hours or more after symptom onset (Sam 2025).
  • Spectrophotometry. Net bilirubin absorbance (NBA) and net oxyhemoglobin absorbance (NOA) are measured between 350 and 600 nm. An NBA ≤0.007 absorbance units with NOA ≤0.02 shows no increase in either pigment. Under the UK guidelines, a raised NBA is corrected for serum bilirubin when serum bilirubin exceeds 20 µmol/L and CSF protein is ≤1.0 g/L (Sjulstad 2025).
  • Visual inspection versus spectrophotometry. In 769 patients with acute headache and a negative CT, sensitivity was 100% for spectrophotometry and 73% for visual inspection, and specificity was 98% and 99% (Sjulstad 2025).
  • Revised UK-NEQAS method. In 543 cases, sensitivity was 100%, specificity 98.1%, positive predictive value 65.9% and negative predictive value 100%. Performance was maintained when lumbar puncture was delayed beyond 24 hours (Sam 2025).

CSF pleocytosis after seizures

  • Early reports. Six patients had transient sterile pleocytosis of 9 to 80 cells/mm³ after repeated generalized convulsions, peaking the day after the seizures stopped (Schmidley 1981).
  • Status epilepticus. Among 138 patients with status epilepticus, 15% had a CSF white cell count of 6 × 10⁶/L or more. The highest count in a patient without an acute insult was 28 × 10⁶/L (Barry 1994).
  • Current interpretation. In two critical care cohorts, every patient with CSF pleocytosis after seizures or within 24 hours of status epilepticus had another identifiable cause (Scramstad 2017; Bajaj 2022). After 24 hours, 4 of 6 pleocytic samples had no cause other than status epilepticus (Bajaj 2022). Pleocytosis is attributed to seizures only after other causes are excluded (Barry 1994).

Thrombocytopenia: Laboratory Approach, Platelet Indices, Immune Thrombocytopenia, Drug-Induced Immune Thrombocytopenia and Neonatal Thrombocytopenia

Definition. Thrombocytopenia results from spurious counting, decreased marrow production, immune or consumptive destruction, splenic sequestration or dilution. Immune thrombocytopenia (ITP) is an acquired disorder with a low platelet count caused by autoimmune platelet destruction and impaired platelet production (Cuker 2026). Primary ITP is a platelet count <100 × 10⁹/L without an identified cause (Mingot-Castellano 2023, citing the Spanish GEPTI 2021 guideline). No reliable marker or confirmatory test exists, and ITP remains a diagnosis of exclusion (Mingot-Castellano 2023).

Related page: Automated Blood Counts, Reticulocyte Count and Peripheral Smear Review (platelet counting principles, EDTA-dependent pseudothrombocytopenia, satellitism and spurious platelet counts) Related page: Inherited Thrombocytopenias, Inherited and Acquired Platelet Function Disorders, and Reactive Versus Clonal Thrombocytosis (inherited thrombocytopenias and the clues that separate them from ITP, platelet function disorders and thrombocytosis) Related page: Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders (aplastic anemia, marrow failure and the approach to other cytopenias) Related page: Anticoagulant Monitoring, DOAC Measurement and Heparin-Induced Thrombocytopenia Testing (heparin-induced thrombocytopenia, VITT and the anti-PF4 disorder classification) Related page: DIC, Thrombotic Microangiopathy and Viscoelastic Testing (DIC, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome and HELLP-associated hemostatic changes) Related page: Hemolytic Disease of the Fetus and Newborn, Fetomaternal Hemorrhage, Rh Immune Globulin and Fetal and Neonatal Transfusion (fetal and neonatal alloimmune thrombocytopenia) Related page: Transfusion Reactions (post-transfusion purpura) Related page: Transfusion Indications, Massive Transfusion, Platelet Refractoriness and Patient Blood Management (platelet transfusion thresholds in adults and neonates)

Laboratory approach to thrombocytopenia by mechanism

Mechanism Causes Laboratory and smear clues Source or related page
Spurious EDTA-dependent platelet agglutination; platelet satellitism Platelet clumps at the feathered edge; normal count in citrate Automated Blood Counts, Reticulocyte Count and Peripheral Smear Review
Decreased production Megaloblastic anemia, myelodysplastic neoplasms and acute leukemias; marrow failure; inherited thrombocytopenias Megaloblastic anemia, myelodysplastic neoplasms and acute leukemias imitate ITP more often with age Mingot-Castellano 2023; Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders; Inherited Thrombocytopenias, Inherited and Acquired Platelet Function Disorders, and Reactive Versus Clonal Thrombocytosis
Immune destruction Primary ITP; secondary ITP; drug-induced immune thrombocytopenia (DITP); heparin-induced thrombocytopenia (HIT); post-transfusion purpura Isolated thrombocytopenia; in primary ITP, large platelets with elevated MPV and immature platelet fraction Mingot-Castellano 2023; Vayne 2020; Transfusion Reactions
Consumption Disseminated intravascular coagulation (DIC); thrombotic microangiopathies (TMA), including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) Schistocytes with microangiopathic hemolysis (low haptoglobin; raised LDH, bilirubin and reticulocytes); prolonged PT and raised fibrin degradation products are not typical of TMA; ADAMTS13 activity <10% in TTP Satoh 2024; DIC, Thrombotic Microangiopathy and Viscoelastic Testing
Sequestration and liver disease Cirrhosis and portal hypertension with hypersplenism Splenomegaly; thrombocytopenia from sequestration, viral marrow suppression, autoantibodies and decreased hepatic TPO production Satoh 2024; Altahan 2025
Toxic Alcohol Myelosuppression, direct platelet toxicity and possibly increased apoptosis Altahan 2025
Dilution and mechanical injury Cardiac surgery, cardiopulmonary bypass, extracorporeal membrane oxygenation (ECMO) Hemodilution, mechanical destruction and inflammation Altahan 2025
  • Liver disease. Thrombocytopenia is present in 6% of patients with chronic hepatitis and in up to 78% of patients with cirrhosis. Decreased hepatic TPO production is the main mechanism (Altahan 2025).
  • Cardiac surgery. Thrombocytopenia complicates more than 30% of cardiac operations and is an independent factor in postoperative morbidity and mortality (Altahan 2025).
  • Smear review. Careful examination of the peripheral smear is mandatory in suspected ITP (Mingot-Castellano 2023). Platelet size and neutrophil inclusions as clues to an inherited thrombocytopenia are taught in Inherited Thrombocytopenias, Inherited and Acquired Platelet Function Disorders, and Reactive Versus Clonal Thrombocytosis.

Platelet count reference method, mean platelet volume and immature platelet fraction

Routine impedance, optical, fluorescence and CD61 counting methods and the effect of EDTA storage on platelet volume are covered in Automated Blood Counts, Reticulocyte Count and Peripheral Smear Review.

  • ICSH and ISLH reference method. Platelets are labeled with two monoclonal antibodies to a CD antigen common to all platelets and counted relative to red cells by fluorescence flow cytometry. At least 50,000 events with a minimum of 1,000 platelet events are acquired at a final 1:1,000 dilution. The platelet count is calculated from the red cell to platelet ratio and the red cell count from a semiautomated single-channel impedance counter. Fresh EDTA venous blood is measured within 4 hours of collection (ICSH 2001).
  • Mean platelet volume (MPV). In primary ITP, platelets are usually large, with elevated MPV and immature platelet fractions (Mingot-Castellano 2023).
  • Immature platelet fraction (IPF). The IPF is the percentage of platelets that are immature and is analogous to the reticulocyte count. The immature platelet count is the IPF multiplied by the platelet count (MacQueen 2017).

Analyzer-specific IPF reference intervals

Analyzer and population IPF reference interval Source
Sysmex XN, 2,104 healthy Korean individuals 1.0%–7.3%; absolute 2.49–15.64 × 10⁹/L Ko 2015
Sysmex XN, 140 umbilical cord blood samples 1.0%–4.4%; absolute 2.94–12.82 × 10⁹/L Ko 2015
Sysmex XN-2000, 153 healthy Spanish adults 1.6%–9.6% Imperiali 2018

The Sysmex XE-2100 interval of 1.1%–6.1% (Briggs 2004) is taught in Automated Blood Counts, Reticulocyte Count and Peripheral Smear Review.

  • Between-analyzer bias. Compared with the XE-2100, the XN showed a positive bias of 1.2% for IPF and 3.0 × 10⁹/L for absolute IPF (Ko 2015). The detection method of the analyzer and the choice of reference individuals contribute to discrepancies between published IPF reference intervals (Wu 2018).
  • Separation of ITP from marrow failure. Median IPF on the XE-5000 was 16.2% in ITP, 10.2% in marrow failure and 2.5% in controls. The two groups overlapped broadly, and the XE-5000 IPF had only some discriminating power (Cybulska 2017).
  • Neonates. Hyporegenerative neonatal thrombocytopenias (syndromes, small for gestational age, birth asphyxia) had lower IPF and immature platelet counts than consumptive thrombocytopenias (immune, infection, DIC, necrotizing enterocolitis) (MacQueen 2017).

Immune thrombocytopenia: terminology and IWG 2009 phases

The International Working Group (IWG) 2009 standardized the terminology, phases, severity grading and response criteria of primary ITP (Rodeghiero 2009).

Term Definition Source
Primary ITP Platelet count <100 × 10⁹/L without an identified cause Mingot-Castellano 2023
Secondary ITP Platelet count <100 × 10⁹/L caused by a diagnosed disease able to induce immune platelet destruction Mingot-Castellano 2023
Newly diagnosed ITP Within 3 months of diagnosis Mingot-Castellano 2023
Persistent ITP 3–12 months from diagnosis Mingot-Castellano 2023
Chronic ITP More than 12 months from diagnosis Mingot-Castellano 2023
Severe ITP Bleeding sufficient to mandate treatment, or new bleeding requiring an increased dose or a different platelet-enhancing agent Mingot-Castellano 2023
Complete response Platelet count ≥100 × 10⁹/L and no bleeding Mingot-Castellano 2023
Response Platelet count ≥30 × 10⁹/L, at least doubling of the baseline count, and no bleeding Mingot-Castellano 2023
No response Platelet count <30 × 10⁹/L, or less than doubling of the baseline count, or bleeding Mingot-Castellano 2023
Corticosteroid dependence Ongoing corticosteroids for at least 2 months to maintain a count ≥30 × 10⁹/L and/or avoid bleeding Mingot-Castellano 2023
  • Refractory ITP: previous and current definitions. The IWG 2009 definition required failure of splenectomy or relapse after it, together with severe ITP or a bleeding risk that requires therapy. Refractoriness has since been redefined as total loss of response to one or more treatments, including rituximab and TPO receptor agonists. The diagnosis of primary ITP is then reconsidered, and bone marrow examination is indicated (Mingot-Castellano 2023).
  • Epidemiology. The incidence of ITP is 1 to 6 per 100,000 adults (Cuker 2026). Prevalence is higher in adults than in children because chronic disease is more frequent in adults (Mingot-Castellano 2023).
  • Intracranial hemorrhage. Among 348,906 ITP hospitalizations in the United States from 2007 to 2016, intracranial hemorrhage occurred in 1.1%, with a mortality of 26.7%. Age ≥65 years (odds ratio 3.69) and gastrointestinal bleeding were associated with it (Bhatt 2020).
  • Pathogenesis. Autoantibodies most often target glycoprotein (GP) IIb/IIIa or GPIb/IX. Platelet destruction involves autoantibodies, phagocytes, complement, apoptosis and hepatic Ashwell-Morell receptor clearance. Decreased production results from antibodies that block TPO function and from increased megakaryocyte apoptosis (Mingot-Castellano 2023).

Diagnosis of primary ITP

The diagnosis requires systematic exclusion of other causes of thrombocytopenia by clinical history, physical examination, CBC and peripheral smear review (Mingot-Castellano 2023).

  • Initial evaluation. Once history, examination, smear review, immunoglobulin levels and viral serology have excluded other disorders, further testing is kept to a minimum because most tests are uninformative. The characteristic laboratory finding is isolated thrombocytopenia (Mingot-Castellano 2023).
  • Antiplatelet antibody testing. Antiplatelet autoantibody assessment is not routinely indicated, although it can be useful in complex cases (Mingot-Castellano 2023). Only 50% to 60% of patients with ITP have detectable platelet autoantibodies in peripheral blood. In 18 patients, adding marrow aspirate testing raised sensitivity from 60% to 72% (Shrestha 2020). In a retrospective study of 368 adults, glycoprotein-specific direct autoantibody testing performed by ISTH recommendations had 90% sensitivity and 78% specificity for active ITP, and all 10 patients who reached remission converted to a negative result (Al-Samkari 2020).
  • Misdiagnosis. About one in seven patients identified as having primary ITP has an incorrect diagnosis (Mingot-Castellano 2023). Bernard-Soulier syndrome is often misdiagnosed as ITP and treated with corticosteroids or even splenectomy (Palma-Barqueros 2021).

Bone marrow examination in suspected ITP

  • Indications. Systematic marrow examination is not recommended. It is indicated for an inadequate response to treatment or when the smear or clinical presentation suggests another disorder. The study includes aspiration, biopsy, flow cytometry, cytogenetics and molecular studies (Mingot-Castellano 2023).
  • Older patients. The incidence of primary ITP reaches 9 per 100,000 per year above 75 years of age. Marrow analysis with cytogenetics and flow cytometry is recommended when reasonable doubt about an age-related mimic arises (Mingot-Castellano 2023).
  • Children. Failure of first-line and second-line treatment prompts marrow examination (Mingot-Castellano 2023).

Secondary immune thrombocytopenia

Secondary forms account for 9%–20% of adult ITP, and the proportion rises with age. SLE is the most common associated disease (Mingot-Castellano 2023).

Associated condition Approximate share of ITP cases Comment Source
Viral infection (CMV, EBV, VZV, Zika virus, HIV, HCV, SARS-CoV-2) 6%–7% Frequent in children; also after vaccination Mingot-Castellano 2023
Systemic lupus erythematosus 5% Most common autoimmune association Mingot-Castellano 2023
Evans syndrome; primary antiphospholipid syndrome 2% each Evans syndrome: corticosteroids first line; ITP with antiphospholipid syndrome treated like SLE-associated ITP Mingot-Castellano 2023
Lymphoproliferative disorders, including CLL 2% Treatment of the underlying disease when it progresses Mingot-Castellano 2023
Autoimmune lymphoproliferative syndrome; CVID; post-transplantation ITP; Helicobacter pylori 1% each Post-transplant cases occur mostly after umbilical cord blood transplantation Mingot-Castellano 2023
  • Helicobacter pylori eradication. In 8 randomized trials (297 patients), eradication lowered the risk of no or minimal response (risk ratio 0.65) and raised the platelet count by a mean of 61.9 × 10⁹/L at about 6 months. Effects on complete response, overall response and relapse were uncertain (Hattab 2026).
  • Vaccines. Vaccines containing an aluminum adjuvant have occasionally been reported to induce ITP (Mingot-Castellano 2023).

Childhood ITP

Primary ITP is usually self-limiting in children. The highest incidence is at 2–8 years of age, a history of a triggering infection is not infrequent, and spontaneous remission occurs even after 2 years. The diagnostic approach is similar to that in adults (Mingot-Castellano 2023).

ITP in pregnancy and gestational thrombocytopenia

Gestational thrombocytopenia accounts for about 80% of thrombocytopenia in pregnancy. Its hallmark is a progressive fall in the platelet count that starts in the mid-second trimester and persists in the third (Mingot-Castellano 2023).

  • Evaluation for ITP. Other pregnancy-related causes are excluded first. The evaluation includes blood pressure, urine protein, hemostatic status, antiphospholipid antibodies and antinuclear antibodies (Mingot-Castellano 2023).
  • Microangiopathic differential. HELLP syndrome belongs to the preeclampsia spectrum and shows schistocytes with a negative Coombs test. Its separation from pregnancy-triggered TTP or complement-mediated HUS can be difficult (Satoh 2024). Hemostatic changes of pregnancy and HELLP are covered in DIC, Thrombotic Microangiopathy and Viscoelastic Testing.
  • Neonate of a mother with ITP. The neonatal platelet count is measured after delivery and repeated daily when it is <100 × 10⁹/L. A count <50 × 10⁹/L prompts cranial ultrasound (Mingot-Castellano 2023). A previous pregnancy with severe neonatal thrombocytopenia identifies a high-risk pregnancy (Mingot-Castellano 2023). A normal maternal count after splenectomy does not prevent transplacental passage of antiplatelet antibodies and neonatal thrombocytopenia (Cuker 2026).

Treatment of adult primary ITP: ASH 2026 and the previous ASH 2019 rules

ASH 2026, a focused update for adults, prefers rituximab or a thrombopoietic agent added to corticosteroids for initial therapy, and a thrombopoietic agent or rituximab after failure of corticosteroids (Cuker 2026). ASH 2019 preferred corticosteroids alone initially and offered splenectomy or a TPO receptor agonist as second-line therapy, with splenectomy delayed for ≥1 year after diagnosis when possible, a delay that ASH 2026 retains; the 2019 recommendations outside the update, including those for children and the treatment threshold, remain current (Cuker 2026, Table 1 reproducing Neunert 2019).

Drug-induced immune thrombocytopenia

More than 300 drugs have at least one confirmed or suspected case of DITP. Laboratory testing established a definite causal relation for 16 drugs: quinine, quinidine, trimethoprim-sulfamethoxazole, vancomycin, penicillin, rifampicin, carbamazepine, ceftriaxone, ibuprofen, mirtazapine, oxaliplatin, suramin, abciximab, tirofiban, eptifibatide and heparin. HIT is more frequent than other DITP and is associated with thrombosis in nearly half of cases. The history includes foods, supplements and beverages that may contain quinine (Vayne 2020).

Mechanisms of drug-induced immune thrombocytopenia

Antibody type Mechanism Example drugs Source
Quinine type Drug binds the antibody complementarity-determining region and increases its affinity for an epitope on GPIIb/IIIa or GPIb/IX; binding occurs only in the presence of the drug Quinine, quinidine, vancomycin, rifampicin, trimethoprim-sulfamethoxazole, nonsteroidal anti-inflammatory drugs, carbamazepine, phenytoin Vayne 2020
Hapten dependent Drug binds covalently to a platelet membrane protein and induces drug-specific antibodies; rare Penicillin and derivatives, cephalosporins Vayne 2020
Fibrinogen receptor antagonist dependent Drug binding changes GPIIb/IIIa conformation and exposes a neoepitope; naturally occurring antibodies cause thrombocytopenia within hours of a first exposure Tirofiban, eptifibatide Vayne 2020
Drug specific Antibodies recognize murine sequences of the chimeric Fab fragment bound to GPIIb/IIIa Abciximab Vayne 2020
Autoantibody induction Drug induces an autoantibody that destroys platelets without the drug Gold salts, procainamide, L-dopa; probably several therapeutic monoclonal antibodies, including PD-1 and CTLA-4 inhibitors Vayne 2020
Immune complexes Drug binds platelet factor 4 (PF4) and induces antibodies that activate platelets through FcγRIIa Heparin, protamine Vayne 2020
  • Timing and severity. Thrombocytopenia typically develops 5 to 10 days after the drug is started (Bakchoul 2018). It develops within hours with abciximab and within 24 hours with tirofiban and eptifibatide. In DITP the nadir is usually <10–20 × 10⁹/L. The median nadir is 10 × 10⁹/L in DITP and 60 × 10⁹/L in HIT (Vayne 2020).
  • Delayed abciximab thrombocytopenia. A fall 5 to 10 days after abciximab occurs because the drug remains on circulating platelets for up to 2 weeks (Vayne 2020).
  • Clinical assessment. Severity of thrombocytopenia, clinical signs, time to onset and use of a drug already implicated in DITP are assessed. Recovery after withdrawal or recurrence on re-exposure supports the causal drug, and rechallenge is performed only at low dose under supervision (Vayne 2020).
  • Recovery. The platelet count usually begins to recover after 4 or 5 half-lives of the drug or its metabolite (Bakchoul 2018).

Laboratory testing for drug-dependent platelet antibodies (ISTH SSC 2015)

The ISTH SSC 2015 recommendations (Arnold 2015) standardize testing for drug-dependent antibodies. Flow cytometry and enzyme immunoassay are used to detect drug-dependent antibodies (Vayne 2020).

Element ISTH SSC 2015 recommendation Source
Timing Sample collected during the acute episode, or at least within 3 weeks of the event Vayne 2020
Anticoagulant Clotted serum or citrated plasma; EDTA avoided Vayne 2020
Target platelets Fresh platelets from healthy group O donors who express HPA-1a, or stored platelets in 0.1% sodium azide Vayne 2020
Methods Donor platelets incubated with patient serum or plasma with and without drug; drug present in all buffers and washes; bound IgG and IgM detected with labeled anti-human antibodies by flow cytometry or enzyme immunoassay Vayne 2020
Drug concentration Therapeutic concentration, for example 0.3 mg/mL for vancomycin; excessive concentrations can give false-positive results Vayne 2020
Controls Positive: serum from a previous patient with DITP, or anti-HPA-1a (WHO standard 106/05) with HPA-1a-positive platelets; negative: serum from a drug-treated patient with a normal count or a healthy control; patient serum tested without drug Vayne 2020
Positive result Antibody binding only in the presence of drug; ratio of signal with drug to signal without drug above 1.5; local cutoffs from 10–20 healthy sera Vayne 2020
  • Definite causation. A definite causal relation requires that the drug or a metabolite is needed for the reaction, that immunoglobulin binding is shown, that platelets are the target and that at least 2 laboratories obtain the same result. Positive results in a single laboratory indicate a probable relation (Vayne 2020).
  • Interpretation. The assays have good specificity and poor sensitivity. A negative result does not exclude DITP, because a metabolite may be responsible, the drug may be poorly soluble or the antibody titer may have fallen in a late sample (Vayne 2020).

Anti-PF4 disorders, thrombotic microangiopathies and post-transfusion purpura

Neonatal thrombocytopenia

  • Definition and frequency. Neonatal thrombocytopenia is a platelet count <150 × 10⁹/L (Chakravorty 2012). Its incidence is slightly below 1% of all neonates at birth, 18%–35% of neonatal intensive care unit (NICU) admissions and about 70% of infants with a birth weight <1,000 g. Severe thrombocytopenia (<50 or <60 × 10⁹/L) affected 2.4% and 5% of NICU admissions in two studies (Ferrer-Marin 2010).
  • Gestational age. In 47,291 neonates, the 5th percentile of the platelet count was 104 × 10⁹/L below 32 weeks of gestation and 123 × 10⁹/L above 32 weeks (Ferrer-Marin 2010).
  • Bleeding. Most major hemorrhages in neonates with severe thrombocytopenia were intraventricular and occurred in the first 2 weeks of life. Intracranial hemorrhage develops in the first week in 25%–31% of neonates with a birth weight <1,500 g, most of whom have a normal platelet count when they bleed (Ferrer-Marin 2010).
Category Usual causes Course Source or related page
Early onset (<72 hours), preterm Placental insufficiency and other antenatal causes; reduced platelet production Mostly mild or moderate; resolves spontaneously Roberts 2003; Chakravorty 2012
Late onset (>72 hours), preterm Bacterial infection and/or necrotizing enterocolitis Rapidly severe (<50 × 10⁹/L) and prolonged Roberts 2003; Chakravorty 2012
Term neonate Fetal and neonatal alloimmune thrombocytopenia (FNAIT), the most important cause High risk of perinatal intracranial hemorrhage Chakravorty 2012; Hemolytic Disease of the Fetus and Newborn, Fetomaternal Hemorrhage, Rh Immune Globulin and Fetal and Neonatal Transfusion
Maternal ITP Transplacental maternal antiplatelet antibodies, including after maternal splenectomy with a normal count Count repeated daily when <100 × 10⁹/L; cranial ultrasound when <50 × 10⁹/L Mingot-Castellano 2023; Cuker 2026
Hyporegenerative Syndromes, small for gestational age, birth asphyxia Low IPF and immature platelet count MacQueen 2017
Consumptive Immune, infection, DIC, necrotizing enterocolitis Higher IPF and immature platelet count MacQueen 2017
Chromosomal anomalies and congenital infection Chromosomal anomalies, including trisomy 18 among fatal cases; congenital cytomegalovirus infection Severe or very severe thrombocytopenia in some cases Resch 2018
Inherited Congenital amegakaryocytic thrombocytopenia, thrombocytopenia-absent radius syndrome and other inherited forms Present from birth Inherited Thrombocytopenias, Inherited and Acquired Platelet Function Disorders, and Reactive Versus Clonal Thrombocytosis
  • Causes in a 23-year cohort. Of 371 thrombocytopenic neonates (1.8 per 1,000 live births), 84.1% had early-onset thrombocytopenia and 76% were preterm. Associated diagnoses were sepsis in 47%, asphyxia in 25%, necrotizing enterocolitis in 4.1%, chromosomal anomalies in 3.9%, hemolytic disease of the newborn in 2.4%, cytomegalovirus infection in 2.4% and neonatal alloimmune thrombocytopenia in 1.0%. Transient thrombocytopenia of unknown origin was always mild (Resch 2018).

Neonatal platelet transfusion thresholds are covered in Transfusion Indications, Massive Transfusion, Platelet Refractoriness and Patient Blood Management.

Inherited Thrombocytopenias, Inherited and Acquired Platelet Function Disorders, and Reactive Versus Clonal Thrombocytosis

Definition. Inherited platelet disorders comprise inherited thrombocytopenias, in which the main defect is a low number of normal-sized, large or small platelets, and inherited platelet function disorders, in which receptors, granules, signal transduction or other platelet components are defective (Palma-Barqueros 2021). Some inherited thrombocytopenias predispose to disorders more dangerous than the thrombocytopenia: kidney failure, hearing loss and cataracts with MYH9 variants, marrow failure with MPL and MECOM variants, and hematologic malignancy with RUNX1, ANKRD26 and ETV6 variants (Noris 2017). Thrombocytosis is a platelet count above 450 × 10⁹/L, and most cases are secondary to another condition (Edahiro 2022).

Related page: Thrombocytopenia: Laboratory Approach, Platelet Indices, Immune Thrombocytopenia, Drug-Induced Immune Thrombocytopenia and Neonatal Thrombocytopenia (laboratory approach to thrombocytopenia, ITP and the frequency of misdiagnosis of inherited thrombocytopenia as ITP) Related page: Von Willebrand Factor Testing and Platelet Function Testing (PFA, light transmission aggregometry, secretion assays, platelet flow cytometry, ISTH-BAT and laboratory patterns of platelet function disorders) Related page: Automated Blood Counts, Reticulocyte Count and Peripheral Smear Review (MYH9-related neutrophil inclusions, Chédiak-Higashi granules and spurious platelet counts) Related page: Classification of Myeloid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry of Myeloid Neoplasms, Clonal Hematopoiesis, VEXAS Syndrome and Germline Predisposition (myeloid neoplasms with germline predisposition) Related page: Myeloproliferative Neoplasms: Chronic Myeloid Leukemia with Molecular Monitoring, Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis and Other Myeloproliferative Neoplasms (essential thrombocythemia criteria and driver mutations) Related page: Laboratory Evaluation of Inborn Errors of Immunity and Secondary Immunodeficiency (Wiskott-Aldrich syndrome and Chédiak-Higashi syndrome immunology)

Recognition of an inherited thrombocytopenia

  • Reasons the genetic origin is missed. Many inherited thrombocytopenias cause a moderately low count with very mild or absent bleeding, so the thrombocytopenia is often an incidental finding in adulthood. The genetic origin is not suspected without a family history, either because inheritance is recessive or because, in up to 40% of patients with MYH9-related disease, the variant has incomplete penetrance or is de novo (Palma-Barqueros 2021).
  • Clues. The diagnosis is based on platelet size on the peripheral smear and on a physical examination that identifies a syndrome. First-line evaluation includes a bleeding history with family history and syndromic features, general biochemical and coagulation tests, and a CBC with smear review of platelet number and morphology and of neutrophil inclusions (Palma-Barqueros 2021).
  • Diagnosis of exclusion. These features increase the risk that ITP is misdiagnosed and treated unnecessarily for years, so inherited thrombocytopenia, like ITP, is a diagnosis of exclusion (Palma-Barqueros 2021).
  • Sequencing. Targeted high-throughput sequencing panels of 10 to 300 genes are the first-line molecular test, and panel-negative cases are analyzed by whole exome or genome sequencing (Palma-Barqueros 2021).
  • Myosin-9 immunofluorescence. In 118 patients with a phenotype consistent with MYH9-related disease, neutrophil myosin-9 aggregates were found in 82, and 80 of these carried an MYH9 variant. Sensitivity was 100% and specificity 95%, and the aggregates are pathognomonic (Savoia 2010).

Inherited thrombocytopenias by platelet size

Inherited thrombocytopenias with large or giant platelets.

Disorder Gene; inheritance Platelet size; thrombocytopenia Associated features Key test or finding Source
MYH9-related disease MYH9; AD Giant; mild to severe Proteinuric nephropathy in 25%, usually progressing to end-stage kidney failure; sensorineural deafness in almost 50%; presenile cataract in 18%; liver disease Neutrophil myosin-9 aggregates by immunofluorescence Palma-Barqueros 2021; Savoia 2010
Bernard-Soulier syndrome, biallelic GP1BA, GP1BB, GP9; AR Giant; moderate to severe Severe bleeding tendency; often misdiagnosed as ITP GPIb-IX-V deficit; laboratory pattern in Von Willebrand Factor Testing and Platelet Function Testing Palma-Barqueros 2021
Bernard-Soulier syndrome, monoallelic GP1BA or GP1BB; AD Large; mild to moderate Absent to mild bleeding; formerly called Mediterranean thrombocytopenia Molecular testing Palma-Barqueros 2021
Gray platelet syndrome NBEAL2; AR Large, gray; mild (Albers 2011) to moderate, usually progressing to severe in adulthood (Palma-Barqueros 2021) Early myelofibrosis; occasional splenomegaly; elevated serum vitamin B12; leukopenia and autoimmunity Selective absence of α-granules by electron microscopy Palma-Barqueros 2021; Albers 2011
GATA1-related disorders GATA1; X-linked Large; mild to severe Dyserythropoiesis with or without anemia, β-thalassemia, neutropenia, splenomegaly or congenital erythropoietic porphyria Dysplastic megakaryocytes; platelet granule deficiency Palma-Barqueros 2021
GFI1B-related thrombocytopenia GFI1B; AD or AR Large; mild to severe Red cell anisopoikilocytosis; aggregation defect Platelet granule deficiency; CD34 expression on platelets Palma-Barqueros 2021
Paris-Trousseau thrombocytopenia and Jacobsen syndrome 11q23 deletion; AD Large; moderate to severe, may improve over time Cardiac, facial, urinary tract, kidney or CNS malformations; intellectual disability Giant platelet granules Palma-Barqueros 2021
FLI1-related thrombocytopenia FLI1; AD or AR Large; mild to moderate Bleeding absent (monoallelic) to moderate (biallelic) Large platelet granules Palma-Barqueros 2021
22q11.2 deletion (DiGeorge and velocardiofacial) syndrome Deletion including GP1BB; AD Large; moderate Cardiac, parathyroid and thymic defects, cognitive delay, facial dysmorphism Molecular testing Palma-Barqueros 2021
ITGA2B/ITGB3-related thrombocytopenia ITGA2B or ITGB3; AD Large; mild to moderate Defective αIIbβ3 expression and activation; moderate bleeding Molecular testing Palma-Barqueros 2021
FLNA-related thrombocytopenia FLNA; X-linked Large; moderate Periventricular nodular heterotopia, skeletal malformations, heart valve dystrophy; also nonsyndromic Molecular testing Palma-Barqueros 2021
TUBB1-related thrombocytopenia TUBB1; AD Large; mild to moderate Absent to mild bleeding Molecular testing Palma-Barqueros 2021
DIAPH1-related thrombocytopenia DIAPH1; AD Large; mild Sensorineural deafness in the first decade; moderate fluctuating neutropenia Molecular testing Palma-Barqueros 2021
SRC-related thrombocytopenia SRC gain of function; AD Large; mild to severe Myelofibrosis, early edentulism, facial dysmorphism Platelet granule defect Palma-Barqueros 2021

Inherited thrombocytopenias with normal-sized platelets.

Disorder Gene; inheritance Thrombocytopenia Associated features Key test or finding Source
Congenital amegakaryocytic thrombocytopenia MPL; AR Very severe from birth Progression to marrow aplasia in childhood; nonsense variants progress within the first decade Absent or reduced marrow megakaryocytes Palma-Barqueros 2021
THPO-related thrombocytopenia THPO; AD (monoallelic) or AR (biallelic) Mild (monoallelic) to severe (biallelic) Biallelic variants cause CAMT-like marrow failure that does not respond to allogeneic HSCT but responds to romiplostim Molecular testing Palma-Barqueros 2021
Thrombocytopenia-absent radius syndrome RBM8A; AR Moderate to severe neonatal; improves with age Bilateral radial aplasia; kidney, cardiac or CNS anomalies Molecular testing Palma-Barqueros 2021
Radioulnar synostosis with amegakaryocytic thrombocytopenia HOXA11 or MECOM; AD Severe neonatal Radioulnar synostosis; possible aplastic anemia in childhood; B-cell deficiency with MECOM Reduced or absent marrow megakaryocytes Palma-Barqueros 2021
Familial platelet disorder with predisposition to AML (FPD/AML) RUNX1; AD Mild to moderate MDS or AML in about 48%; increased risk of lymphoblastic leukemia; aspirin-like function defect with α- and dense-granule deficiency Molecular testing; baseline marrow examination with cytogenetics Palma-Barqueros 2021
ANKRD26-related thrombocytopenia ANKRD26; AD Mild to moderate MDS or AML in about 7% of patients; increased hemoglobin or leukocytes in some Molecular testing Palma-Barqueros 2021
ETV6-related thrombocytopenia ETV6; AD Mild to moderate ALL in 21%, and AML, MDS, multiple myeloma or polycythemia vera in another 7%; red cells with high MCV Molecular testing Palma-Barqueros 2021

Inherited thrombocytopenias with small platelets.

Disorder Gene; inheritance Platelet size; thrombocytopenia Associated features Key test or finding Source
Wiskott-Aldrich syndrome WAS; X-linked Small (MPV 3.5–7 fL); counts 5–50 × 10⁹/L Eczema, combined immunodeficiency, autoimmunity in about 40%, lymphoma risk Molecular testing Palma-Barqueros 2021
X-linked thrombocytopenia WAS hypomorphic variants; X-linked Small; moderate to severe Mild form of Wiskott-Aldrich syndrome; possible immunodeficiency and mild eczema; increased risk of malignancy and autoimmune disorders, lower than in the classic syndrome Molecular testing Palma-Barqueros 2021
  • Relative frequency. MYH9-related disease is the most common inherited thrombocytopenia worldwide, with more than 300 families reported. ANKRD26-, ETV6- and RUNX1-related thrombocytopenias account for 18%, 3% and 5% of inherited thrombocytopenias, almost one quarter together. In all three, the marrow shows normal or increased megakaryocytes with dysplastic features such as small hypolobulated nuclei (Palma-Barqueros 2021).
  • Platelet-type VWD. Gain-of-function GP1BA variants cause an autosomal dominant disorder in which the count can be normal and falls under stress (Palma-Barqueros 2021). Its laboratory separation from type 2B VWD is covered in Von Willebrand Factor Testing and Platelet Function Testing.
  • Leukemia predisposition. Germline RUNX1, ETV6 and ANKRD26 variants carry estimated lifetime risks of hematologic malignancy of about 45%, 30% and 4.9% (Downes 2020). A baseline marrow examination with cytogenetics and annual blood counts, smear review and clinical evaluation are recommended, and related stem cell donors are tested for the family variant (Palma-Barqueros 2021). Classification of the resulting myeloid neoplasms is covered in Classification of Myeloid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry of Myeloid Neoplasms, Clonal Hematopoiesis, VEXAS Syndrome and Germline Predisposition.

Inherited platelet function disorders: clinical and genetic features

Inherited platelet disorders cause spontaneous mucocutaneous bleeding from childhood (epistaxis, gum bleeding, purpura, menorrhagia), usually moderate and worse with trauma, drugs, surgery or childbirth (Palma-Barqueros 2021). Laboratory patterns on aggregometry, secretion assays and flow cytometry are covered in Von Willebrand Factor Testing and Platelet Function Testing.

Disorder Defect Gene; inheritance Clinical and morphologic features Source
Glanzmann thrombasthenia Integrin αIIbβ3 (GPIIb/IIIa) ITGA2B, ITGB3; AR Normal count and morphology; type I <5% residual αIIbβ3, type II 10%–20%, variant >50% nonfunctional receptor; moderate to severe bleeding from childhood in homozygotes; heterozygotes usually asymptomatic Palma-Barqueros 2021
Bernard-Soulier syndrome GPIb-IX-V complex GP1BA, GP1BB, GP9; AR Giant platelets with thrombocytopenia (large-platelet table) Palma-Barqueros 2021
ADP receptor deficiency P2Y12 P2RY12; AD or AR Normal count and morphology; mild to moderate bleeding, mostly with antiplatelet drugs or procedures Palma-Barqueros 2021
Thromboxane A2 receptor deficiency TPα receptor TBXA2R; AD or AR Normal count and morphology; mild to moderate bleeding Palma-Barqueros 2021
Thromboxane synthesis defects COX-1, thromboxane synthase, cytosolic phospholipase A2 PTGS1, TBXAS1, PLA2G4A; AR or AD Osteoporosis in Ghosal syndrome (TBXAS1); recurrent gastrointestinal ulceration with PLA2G4A defects Palma-Barqueros 2021
Collagen receptor defect GPVI GP6; AR Normal count and morphology; mild to moderate bleeding Palma-Barqueros 2021
CalDAG-GEF1 deficiency αIIbβ3 inside-out activation RASGRP2; AR Normal count and morphology Palma-Barqueros 2021
Leukocyte adhesion deficiency type III Kindlin-3 FERMT3; AR Infections, poor wound healing, osteopetrosis; bleeding more severe than in Glanzmann thrombasthenia Palma-Barqueros 2021
Hermansky-Pudlak syndrome Dense (δ) granules HPS1–HPS11 (including AP3B1, DTNBP1, AP3D1); AR Oculocutaneous albinism, ceroid accumulation in mononuclear phagocytes, pulmonary fibrosis, granulomatous colitis, neutropenia or immunodeficiency by subtype; severity linked to the gene, especially HPS1 and HPS4 Palma-Barqueros 2021
Chédiak-Higashi syndrome Dense granules; lysosomal trafficking LYST; AR Dense granule deficiency; leukocyte and clinical features taught in Automated Blood Counts, Reticulocyte Count and Peripheral Smear Review Palma-Barqueros 2021
Griscelli syndromes Dense granules; organelle transport RAB27A, MYO5A, MLPH; AR Partial albinism, silver hair, neurologic defects, lymphohistiocytosis Palma-Barqueros 2021
Isolated δ-storage pool disease Dense granules Not identified; AD or AR Normal count; absent or mild bleeding Palma-Barqueros 2021
Gray platelet syndrome α-granules NBEAL2; AR Clinical features in the large-platelet table Palma-Barqueros 2021
Quebec platelet disorder α-granule protein defect with increased fibrinolytic activity PLAU; AD Moderate thrombocytopenia with normal morphology; absent or reduced aggregation with epinephrine; bleeding responds to antifibrinolytics and not to platelet transfusion Palma-Barqueros 2021
Scott syndrome Procoagulant phospholipid exposure ANO6 (TMEM16F); AR Normal count and morphology; decreased microparticle generation and annexin V binding by flow cytometry; moderate to severe bleeding with childbirth or dental procedures Palma-Barqueros 2021
Stormorken syndrome Store-operated calcium entry STIM1, ORAI1; AD Moderate thrombocytopenia; tubular aggregate myopathy, congenital miosis, asplenia, ichthyosis Palma-Barqueros 2021
  • Electron microscopy. Electron microscopy shows the δ-granule defect of Hermansky-Pudlak syndrome, Chédiak-Higashi syndrome and isolated δ-storage pool disease (Palma-Barqueros 2021).
  • Gray platelet syndrome genetics. GATA1, VPS33B, VIPAS39, GFI1B and PLAU variants also cause α-granule deficiency, and whether these disorders are classified as gray platelet syndrome is debated (Palma-Barqueros 2021).

Diagnostic pathway and gene panels for inherited platelet disorders

  • ISTH SSC 2015 guidance. After clinical and laboratory screening, light transmission aggregometry, platelet secretion assays and flow cytometry are the first-line diagnostic tests for heritable platelet function disorders (Burley 2026, summarizing Gresele 2015). The guidance on the PFA, the bleeding time and the ISTH-BAT is taught in Von Willebrand Factor Testing and Platelet Function Testing.
  • Sequencing. A gene panel is the preferred strategy when platelet function testing does not discriminate. Targeted high-throughput sequencing found pathogenic or likely pathogenic variants in about 30%–50% of patients with suspected heritable platelet disorders, with higher yields in heritable thrombocytopenias than in isolated platelet function disorders (Burley 2026). Most guidelines recommend disease-specific targeted or virtual panels of curated genes to limit unsolicited findings, and the diagnostic rate depends strongly on patient inclusion criteria (Downes 2020).
  • Unsolicited findings and consent. A pathogenic RUNX1, ETV6 or ANKRD26 variant found during testing for thrombocytopenia can reveal leukemia risk in a patient without a family history. Consent before testing explains possible unsolicited findings and allows the patient to opt out. Carrier status is reported when consent was obtained (Downes 2020).

Acquired platelet dysfunction

Uremic platelet dysfunction and antiplatelet drug monitoring are covered in Von Willebrand Factor Testing and Platelet Function Testing.

Cause Mechanism Effect on platelets Source
Aspirin Irreversible COX-1 inhibition reduces thromboxane A2 Impaired aggregation for the platelet lifespan, 7–10 days Altahan 2025
Other NSAIDs (ibuprofen, naproxen, indomethacin) Reversible COX-1 inhibition Impaired aggregation for about 24 hours Altahan 2025
αIIbβ3 antagonists (abciximab, tirofiban, eptifibatide) Integrin blockade Impaired aggregation to all agonists; rare immune thrombocytopenia Altahan 2025
Acute alcohol ingestion Impaired arachidonic acid mobilization; reduced αIIbβ3 expression Impaired aggregation to several agonists Altahan 2025
Myeloproliferative neoplasms Clonal megakaryopoiesis; acquired von Willebrand syndrome at high counts (taught in Von Willebrand Factor Testing and Platelet Function Testing) Defects of aggregation, granule content, surface glycoproteins and fibrinogen binding; JAK2-mutated platelets can be hyperactive; laboratory defects do not correlate with bleeding Altahan 2025
Myelodysplastic neoplasms Clonal hematopoiesis Reduced α-granules and dense tubular system abnormalities; bleeding more severe than the count predicts Altahan 2025
Paraproteinemia and lymphoproliferative disorders (myeloma, Waldenström macroglobulinemia, CLL, MGUS) Nonspecific paraprotein binding to platelet receptors; IgM hyperviscosity Impaired adhesion and aggregation Altahan 2025
Liver disease Increased platelet cAMP and cGMP impair aggregation; reduced prostacyclin and nitric oxide synthesis in portal hypertension and elevated VWF promote hyperactivity Hypofunction and hyperfunction coexist in a rebalanced hemostatic state Altahan 2025
Cardiopulmonary bypass, ECMO, prosthetic devices Artificial surfaces, shear stress, hypothermia, receptor shedding Platelet activation and exhaustion with thrombocytopenia Altahan 2025
Inhibitory autoantibodies Antibodies block GPIIb/IIIa or GPIb-IX-V Acquired Glanzmann thrombasthenia or Bernard-Soulier syndrome; bleeding out of proportion to the count; glycoprotein expression by flow cytometry usually intact with defective aggregation Altahan 2025

Reactive versus clonal thrombocytosis

Essential thrombocythemia criteria and driver mutation frequencies are covered in Myeloproliferative Neoplasms: Chronic Myeloid Leukemia with Molecular Monitoring, Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis and Other Myeloproliferative Neoplasms. Spurious platelet counts from microcytes, schistocytes and cytoplasmic fragments are covered in Automated Blood Counts, Reticulocyte Count and Peripheral Smear Review.

Causes of thrombocytosis in three cohorts

Cohort Primary (clonal) Secondary (reactive) Leading secondary causes Source
1,202 adults, count >450 × 10⁹/L 12.5% (essential thrombocythemia 70.7%, polycythemia vera 17.3%) 83.1%; cause not identified in 4.4% Tissue injury 32.2%, infection 17.1%, chronic inflammatory disorders 11.7%, iron deficiency anemia 11.1%, malignancy 9.5% Edahiro 2022
801 patients, count >500 × 10⁹/L 5.2% Noninfectious 50.6%; infectious 47.9% Tissue damage, malignancy, iron deficiency anemia, chronic inflammation, drugs, splenectomy; soft-tissue, pulmonary and gastrointestinal infection Rose 2012
732 patients, count ≥500 × 10⁹/L 12.3% (essential thrombocythemia in 45% of these) 87.7% Tissue damage 42%, infection 24% Griesshammer 1999

Features that separate reactive from clonal thrombocytosis

Feature Reactive thrombocytosis Clonal thrombocytosis Source
Median platelet count 518 × 10⁹/L 786 × 10⁹/L Edahiro 2022
Count >700 × 10⁹/L 8.9% 64.7% Edahiro 2022
Count >1,000 × 10⁹/L 0.6% 30% Edahiro 2022
Hemoglobin and leukocytes Lower median hemoglobin (11.0 g/dL) and leukocytes (7.8 × 10⁹/L) Higher median hemoglobin (13.6 g/dL) and leukocytes (9.2 × 10⁹/L) Edahiro 2022
Lactate dehydrogenase Lower Higher Griesshammer 1999; Edahiro 2022
History of thrombosis related to thrombocytosis 1.2% (Edahiro 2022); venous only and only with other risk factors (Griesshammer 1999) 15.3% (Edahiro 2022); arterial and venous (Griesshammer 1999) Edahiro 2022; Griesshammer 1999
Duration Faster normalization when infection is the cause Extreme (>800 × 10⁹/L) and prolonged (>1 month) counts more frequent Rose 2012
  • Molecular markers. At least one MPN molecular marker was present in 86% of patients with primary thrombocytosis. Driver mutations were not analyzed in every patient classified as secondary (Edahiro 2022).
  • Clues to infection. Fever, tachycardia, weight loss, hypoalbuminemia, neutrophilia, leukocytosis and anemia were associated with an infectious cause. Thrombocytosis from infection normalized faster but carried a higher risk of death than other secondary causes (Rose 2012).
  • Malignancy. Lung, gastric, esophageal, pharyngeal and colorectal cancers and lymphoma were the most frequent malignancies associated with thrombocytosis (Edahiro 2022).
  • Iron deficiency. Iron deficiency anemia is frequently accompanied by reactive thrombocytosis. Reduced transferrin receptor 2 signaling and ERK activation bias megakaryocyte-erythroid progenitors toward the megakaryocytic lineage, and the HIF-2α and VEGF pathway is a further candidate mechanism. Management relies on iron repletion (Facco 2026).
  • Post-splenectomy thrombocytosis. Thrombocytosis follows about 80% of splenectomies. JAK2 V617F was not detected in any of 27 patients with post-splenectomy thrombocytosis referred for testing, and CALR mutations were absent in the 12 tested. Routine testing is not warranted. It may be justified when splenectomy followed an event suggesting essential thrombocythemia, such as splenic rupture, splenomegaly with splenic infarcts or Budd-Chiari syndrome (Langabeer 2020).
  • Infants. Among 20,818 infants in 2 tertiary neonatal intensive care units, thrombocytosis (>500 × 10⁹/L) occurred in 3% (8% of preterm infants) and extreme thrombocytosis (>1,000 × 10⁹/L) in 0.08%. Thrombocytosis was associated with leukocytosis and relative anemia, and no thrombotic or bleeding complications followed (Rajagopalan 2026).
  • Alcohol withdrawal. Rebound thrombocytosis occurs 1–3 weeks after cessation of heavy alcohol intake, followed by normalization (Altahan 2025).

References

  1. Abdelfadiel O, Abdalla M, Ross IL. Biochemical predictors and clinical characteristics for the development of cytopenia and bone marrow involvement among patients with primary hyperparathyroidism. Int J Endocrinol. 2026;2026:4158433. doi:10.1155/ije/4158433. PMID 42517068 (Abdelfadiel 2026)
  2. Abu Isneina SA, Mayyala WA, Madia A, et al. Malignancy-mimicking osteitis fibrosa cystica secondary to primary hyperparathyroidism. J Surg Case Rep. 2026;2026(8):rjag749. doi:10.1093/jscr/rjag749. PMID 42670464 (Abu Isneina 2026)
  3. Al-Samkari H, Rosovsky RP, Karp Leaf RS, et al. A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. Blood Adv. 2020;4(1):9–18. doi:10.1182/bloodadvances.2019000868. PMID 31891657. Abstract only (Al-Samkari 2020)
  4. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi:10.1038/s41375-022-01620-2. PMID 35732829 (Alaggio 2022)
  5. Albers CA, Cvejic A, Favier R, et al. Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat Genet. 2011;43(8):735–737. doi:10.1038/ng.885. PMID 21765411. Abstract only (Albers 2011)
  6. Altahan RM. Acquired platelet disorders. Front Med (Lausanne). 2025;12:1638994. doi:10.3389/fmed.2025.1638994. PMID 41306494 (Altahan 2025)
  7. Ansari AZ, Haque ZI, Mokodanski NA, et al. Atypical presentation of Bordetella pertussis in a six-month-old with cleaved lymphocytes and mild respiratory distress. Cureus. 2025;17(6):e85395. doi:10.7759/cureus.85395. PMID 40621272 (Ansari 2025)
  8. Arnold DM, Curtis BR, Bakchoul T, et al. Recommendations for standardization of laboratory testing for drug-induced immune thrombocytopenia: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(4):676–678. doi:10.1111/jth.12852. PMID 25604471 (Arnold 2015)
  9. Ayyanar P, Kar R, Dubashi B, Basu D. Post-chemotherapy changes in bone marrow in acute leukemia with emphasis on detection of residual disease by immunohistochemistry. Cureus. 2021;13(12):e20175. doi:10.7759/cureus.20175. PMID 35004001. Abstract only (Ayyanar 2021)
  10. Bailey JW, Williams J, Bain BJ, et al. Guideline: the laboratory diagnosis of malaria. General Haematology Task Force of the British Committee for Standards in Haematology. Br J Haematol. 2013;163(5):573–580. doi:10.1111/bjh.12572. PMID 24219330 (Bailey 2013)
  11. Bain BJ. Bone marrow biopsy morbidity and mortality. Br J Haematol. 2003;121(6):949–951. doi:10.1046/j.1365-2141.2003.04329.x. PMID 12786808 (Bain 2003)
  12. Bain BJ. Bone marrow biopsy morbidity: review of 2003. J Clin Pathol. 2005;58(4):406–408. doi:10.1136/jcp.2004.022178. PMID 15790706 (Bain 2005)
  13. Bain BJ. The bone marrow aspirate of healthy subjects. Br J Haematol. 1996;94(1):206–209. doi:10.1046/j.1365-2141.1996.d01-1786.x. PMID 8757536 (Bain 1996)
  14. Bajaj S, Griesdale D, Agha-Khani Y, Moien-Afshari F. Cerebrospinal fluid pleocytosis not attributable to status epilepticus in first 24 hours. Can J Neurol Sci. 2022;49(2):210–217. doi:10.1017/cjn.2021.83. PMID 33902768 (Bajaj 2022)
  15. Bakchoul T, Marini I. Drug-associated thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2018;2018(1):576–583. doi:10.1182/asheducation-2018.1.576. PMID 30504360 (Bakchoul 2018)
  16. Banerjee R, Halil O, Bain BJ, Cummins D, Banner NR. Neutrophil dysplasia caused by mycophenolate mofetil. Transplantation. 2000;70(11):1608–1610. doi:10.1097/00007890-200012150-00012. PMID 11152223 (Banerjee 2000)
  17. Barry E, Hauser WA. Pleocytosis after status epilepticus. Arch Neurol. 1994;51(2):190–193. doi:10.1001/archneur.1994.00540140100019. PMID 8304844 (Barry 1994)
  18. Beaton B, Ramaswami U, Hughes DA, et al. Abundant pseudo-Gaucher cells result in delay in diagnosis of plasma cell myeloma. Br J Haematol. 2018;182(4):465. doi:10.1111/bjh.15257. PMID 29741764 (Beaton 2018)
  19. Ben-Horin S, Shinfeld A, Kachel E, Chetrit A, Livneh A. The composition of normal pericardial fluid and its implications for diagnosing pericardial effusions. Am J Med. 2005;118(6):636–640. doi:10.1016/j.amjmed.2005.01.066. PMID 15922695 (Ben-Horin 2005)
  20. Bhatt P, Yagnik PJ, Ayensu M, et al. Temporal trends of intracranial hemorrhage among immune thrombocytopenia hospitalizations in the United States. Cureus. 2020;12(7):e9427. doi:10.7759/cureus.9427. PMID 32864253. Abstract only (Bhatt 2020)
  21. Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis: United States. MMWR Recomm Rep. 2016;65(2):1–44. doi:10.15585/mmwr.rr6502a1. PMID 27172113 (Biggs 2016)
  22. Book R, Ben-Ezra J, Glait Santar C, et al. Lymphoid aggregates in the bone marrow biopsies of patients with myelodysplastic syndromes: a potential prognostic marker? Front Oncol. 2022;12:988998. doi:10.3389/fonc.2022.988998. PMID 36776361. Abstract only (Book 2022)
  23. Bourner G, De la Salle B, George T, et al. ICSH guidelines for the verification and performance of automated cell counters for body fluids. Int J Lab Hematol. 2014;36(6):598–612. doi:10.1111/ijlh.12196. PMID 24628711 (Bourner 2014)
  24. Bourrienne MC, Ben Salah I, de Raucourt E, et al. Pancytopenia related to acquired sea-blue histiocytosis during chronic parenteral nutrition. Am J Hematol. 2024;99(5):971–972. doi:10.1002/ajh.27185. PMID 38115676 (Bourrienne 2024)
  25. Brigden ML, Au S, Thompson S, et al. Infectious mononucleosis in an outpatient population: diagnostic utility of 2 automated hematology analyzers and the sensitivity and specificity of Hoagland's criteria in heterophile-positive patients. Arch Pathol Lab Med. 1999;123(10):875–881. doi:10.5858/1999-123-0875-IMIAOP. PMID 10506437 (Brigden 1999)
  26. Briggs C, Kunka S, Hart D, Oguni S, Machin SJ. Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia. Br J Haematol. 2004;126(1):93–99. doi:10.1111/j.1365-2141.2004.04987.x. PMID 15198738 (Briggs 2004)
  27. Brown L, Hoa NT, Ly VT, et al. Recent advances in the diagnosis of talaromycosis. Clin Infect Dis. 2026;81(6):e533–e543. doi:10.1093/cid/ciaf253. PMID 40569093 (Brown 2026)
  28. Burley K, Cornish N, Carretero MM, Westbury SK. Testing for non-severe heritable platelet function disorders. Int J Lab Hematol. 2026;48(6):1279–1288. doi:10.1111/ijlh.70192. PMID 42399108 (Burley 2026)
  29. Calvanese V, Mikkola HKA. The genesis of human hematopoietic stem cells. Blood. 2023;142(6):519–532. doi:10.1182/blood.2022017934. PMID 37339578. Abstract only (Calvanese 2023)
  30. Camou F, Berger MG. Gaucher disease, state of the art and perspectives. J Intern Med. 2025;298(3):155–172. doi:10.1111/joim.20114. PMID 40611398 (Camou 2025)
  31. Campbell JK, Matthews JP, Seymour JF, et al. Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma. Ann Oncol. 2003;14(2):273–276. doi:10.1093/annonc/mdg055. PMID 12562655 (Campbell 2003)
  32. Cantadori LO, Gaiolla RD, Niero-Melo L, Oliveira CC. Bone marrow aspirate clot: a useful technique in diagnosis and follow-up of hematological disorders. Case Rep Hematol. 2019;2019:7590948. doi:10.1155/2019/7590948. PMID 30984433. Abstract only (Cantadori 2019)
  33. Carvalho JA, Pereira S, Boavida L, et al. Bone marrow granulomatosis in acute Q fever. Cureus. 2021;13(10):e18782. doi:10.7759/cureus.18782. PMID 34796070 (Carvalho 2021)
  34. Centers for Disease Control and Prevention. DPDx: Babesiosis. https://www.cdc.gov/dpdx/babesiosis/index.html (accessed 2026-11-17). (CDC 2026d)
  35. Centers for Disease Control and Prevention. DPDx: Blood specimens: microscopic examination. https://www.cdc.gov/dpdx/diagnosticprocedures/blood/microexam.html (accessed 2026-11-17). (CDC 2026c)
  36. Centers for Disease Control and Prevention. DPDx: Blood specimens: specimen processing. https://www.cdc.gov/dpdx/diagnosticprocedures/blood/specimenproc.html (accessed 2026-11-17). (CDC 2026a)
  37. Centers for Disease Control and Prevention. DPDx: Leishmaniasis. https://www.cdc.gov/dpdx/leishmaniasis/index.html (accessed 2026-11-17). (CDC 2026j)
  38. Centers for Disease Control and Prevention. DPDx: Loiasis. https://www.cdc.gov/dpdx/loiasis/index.html (accessed 2026-11-17). (CDC 2026h)
  39. Centers for Disease Control and Prevention. DPDx: Lymphatic filariasis. https://www.cdc.gov/dpdx/lymphaticfilariasis/index.html (accessed 2026-11-17). (CDC 2026g)
  40. Centers for Disease Control and Prevention. DPDx: Malaria. https://www.cdc.gov/dpdx/malaria/index.html (accessed 2026-11-17). (CDC 2026b)
  41. Centers for Disease Control and Prevention. DPDx: Mansonellosis. https://www.cdc.gov/dpdx/mansonellosis/index.html (accessed 2026-11-17). (CDC 2026i)
  42. Centers for Disease Control and Prevention. DPDx: Trypanosomiasis, African. https://www.cdc.gov/dpdx/trypanosomiasisafrican/index.html (accessed 2026-11-17). (CDC 2026f)
  43. Centers for Disease Control and Prevention. DPDx: Trypanosomiasis, American. https://www.cdc.gov/dpdx/trypanosomiasisamerican/index.html (accessed 2026-11-17). (CDC 2026e)
  44. Chakravorty S, Roberts I. How I manage neonatal thrombocytopenia. Br J Haematol. 2012;156(2):155–162. doi:10.1111/j.1365-2141.2011.08892.x. PMID 21950766 (Chakravorty 2012)
  45. Cho J, Oh J, Lee SG, et al. Performance evaluation of body fluid cellular analysis using the Beckman Coulter UniCel DxH 800, Sysmex XN-350, and UF-5000 automated cellular analyzers. Ann Lab Med. 2020;40(2):122–130. doi:10.3343/alm.2020.40.2.122. PMID 31650728 (Cho 2020)
  46. Choi SE, Hong SW, Yoon SO. Proposal of an appropriate decalcification method of bone marrow biopsy specimens in the era of expanding genetic molecular study. J Pathol Transl Med. 2015;49(3):236–242. doi:10.4132/jptm.2015.03.16. PMID 26018515 (Choi 2015)
  47. Chung HJ, Chi HS, Cho YU, et al. Bone marrow fibrin-ring granuloma: review of 24 cases [in Korean]. Korean J Lab Med. 2007;27(3):182–187. doi:10.3343/kjlm.2007.27.3.182. PMID 18094573 (Chung 2007)
  48. Chung HJ, Chi HS, Jang S, et al. Epstein-Barr virus infection associated with bone marrow fibrin-ring granuloma. Am J Clin Pathol. 2010;133(2):300–304. doi:10.1309/AJCPB7SX7QXASPSK. PMID 20093240 (Chung 2010)
  49. Clark MR, Mandal M, Ochiai K, et al. Orchestrating B cell lymphopoiesis through interplay of IL-7 receptor and pre-B cell receptor signalling. Nat Rev Immunol. 2014;14(2):69–80. doi:10.1038/nri3570. PMID 24378843 (Clark 2014)
  50. Cuker A, Terrell DR, Sowdagar H, et al. American Society of Hematology 2026 guidelines for immune thrombocytopenia: initial and second-line therapy for adults with primary ITP. Blood Adv. 2026;10(20):7076–7097. doi:10.1182/bloodadvances.2026021269. PMID 42617047 (Cuker 2026)
  51. Cybulska A, Meintker L, Ringwald J, Krause SW. Measurements of immature platelets with haematology analysers are of limited value to separate immune thrombocytopenia from bone marrow failure. Br J Haematol. 2017;177(4):612–619. doi:10.1111/bjh.14628. PMID 28378905 (Cybulska 2017)
  52. De Paschale M, Clerici P. Serological diagnosis of Epstein-Barr virus infection: problems and solutions. World J Virol. 2012;1(1):31–43. doi:10.5501/wjv.v1.i1.31. PMID 24175209 (De Paschale 2012)
  53. de Porto AP, Lammers AJ, Bennink RJ, et al. Assessment of splenic function. Eur J Clin Microbiol Infect Dis. 2010;29(12):1465–1473. doi:10.1007/s10096-010-1049-1. PMID 20853172 (de Porto 2010)
  54. Downes K, Borry P, Ericson K, et al. Clinical management, ethics and informed consent related to multi-gene panel-based high throughput sequencing testing for platelet disorders: communication from the SSC of the ISTH. J Thromb Haemost. 2020;18(10):2751–2758. doi:10.1111/jth.14993. PMID 33079472 (Downes 2020)
  55. Edahiro Y, Kurokawa Y, Morishita S, et al. Causes of thrombocytosis: a single-center retrospective study of 1,202 patients. Intern Med. 2022;61(22):3323–3328. doi:10.2169/internalmedicine.9282-21. PMID 36385045 (Edahiro 2022)
  56. Erber WN, Tzankov A, Pozdnyakova O, et al. ICSH guidance on bone marrow examination and reporting. Int J Lab Hematol. 2026. doi:10.1111/ijlh.70214. PMID 42695770 (Erber 2026)
  57. Etzell JE, Wang E. Acquired Pelger-Huët anomaly in association with concomitant tacrolimus and mycophenolate mofetil in a liver transplant patient: a case report and review of the literature. Arch Pathol Lab Med. 2006;130(1):93–96. doi:10.5858/2006-130-93-APAIAW. PMID 16390246 (Etzell 2006)
  58. Evans MG, Brynes RK, Crymes A, et al. Role of immunoglobulin heavy and light chain gene rearrangement analysis in differentiating between benign and malignant bone marrow B-cell lymphoid aggregates. Hum Pathol. 2022;130:58–64. doi:10.1016/j.humpath.2022.10.004. PMID 36252861 (Evans 2022)
  59. Facco JV, Krause DS, Olalla Saad ST. Mechanisms of thrombocytosis in iron-deficiency anemia. Eur J Haematol. 2026;117(4):728–738. doi:10.1111/ejh.70211. PMID 42097980 (Facco 2026)
  60. Ferrer-Marin F, Liu ZJ, Gutti R, Sola-Visner M. Neonatal thrombocytopenia and megakaryocytopoiesis. Semin Hematol. 2010;47(3):281–288. doi:10.1053/j.seminhematol.2010.04.002. PMID 20620440 (Ferrer-Marin 2010)
  61. Fotso Fotso A, Drancourt M. Laboratory diagnosis of tick-borne African relapsing fevers: latest developments. Front Public Health. 2015;3:254. doi:10.3389/fpubh.2015.00254. PMID 26618151 (Fotso Fotso 2015)
  62. Gajendra S, Sachdev R. Pseudo-Gaucher cells in thalassemia intermedia. Int J Surg Pathol. 2015;23(5):370–371. doi:10.1177/1066896915585349. PMID 25957296 (Gajendra 2015)
  63. Girard S, Pettazzoni M, Froissart R, et al. How to diagnose acid sphingomyelinase deficiency (ASMD) and Niemann-Pick disease type C from bone marrow and peripheral blood smears. HemaSphere. 2024;8(11):e70042. doi:10.1002/hem3.70042. PMID 39507854 (Girard 2024)
  64. Goyal S, Singh UR, Rusia U. Comparative evaluation of bone marrow aspirate with trephine biopsy in hematological disorders and determination of optimum trephine length in lymphoma infiltration. Mediterr J Hematol Infect Dis. 2014;6(1):e2014002. doi:10.4084/MJHID.2014.002. PMID 24455111 (Goyal 2014)
  65. Gresele P; Subcommittee on Platelet Physiology of the International Society on Thrombosis and Hemostasis. Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH. J Thromb Haemost. 2015;13(2):314–322. doi:10.1111/jth.12792. PMID 25403439 (Gresele 2015)
  66. Griesshammer M, Bangerter M, Sauer T, et al. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med. 1999;245(3):295–300. doi:10.1046/j.1365-2796.1999.00452.x. PMID 10205592 (Griesshammer 1999)
  67. Grozovsky R, Begonja AJ, Liu K, et al. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat Med. 2015;21(1):47–54. doi:10.1038/nm.3770. PMID 25485912 (Grozovsky 2015)
  68. Gunaratne MDSK, Shi M, Go RS. A comprehensive review on gelatinous transformation of the bone marrow. Expert Rev Hematol. 2024;17(9):547–554. doi:10.1080/17474086.2024.2385472. PMID 39060221 (Gunaratne 2024)
  69. Haddadin R, Ghobrial M, Tabbah T, et al. How do polymorphonuclear counts in ascitic fluid correlate to hospital outcome. J Community Hosp Intern Med Perspect. 2025;15(3):15–22. doi:10.55729/2000-9666.1475. PMID 40755993 (Haddadin 2025)
  70. Hanley TM. Renal osteodystrophy in a case of suspected plasma cell neoplasm. EJHaem. 2026;7(5):e70421. doi:10.1002/jha2.70421. PMID 42812588 (Hanley 2026)
  71. Hassoun H, Roshal M, Sabari J, et al. Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance. Leuk Lymphoma. 2017;58(12):2962–2965. doi:10.1080/10428194.2017.1312382. PMID 28482750 (Hassoun 2017)
  72. Hattab M, Milhem F, Jallad H, et al. Helicobacter pylori eradication for immune thrombocytopenia reduces non-response and raises platelet counts: meta-analysis of randomized trials. Ann Hematol. 2026;105(11):473. doi:10.1007/s00277-026-07187-7. PMID 42911235. Abstract only (Hattab 2026)
  73. Hitchcock IS, Kaushansky K. Thrombopoietin from beginning to end. Br J Haematol. 2014;165(2):259–268. doi:10.1111/bjh.12772. PMID 24499199 (Hitchcock 2014)
  74. Hou Y, Zhang ZH, Li WQ, et al. Prolyl hydroxylase domain proteins: localization, regulation, function and their role in erythropoiesis (review). Mol Med Rep. 2026;33(3). doi:10.3892/mmr.2026.13792. PMID 41543162 (Hou 2026)
  75. Imperiali CE, Arbiol-Roca A, Sanchez-Navarro L, et al. Reference interval for immature platelet fraction on Sysmex XN haematology analyser in adult population. Biochem Med (Zagreb). 2018;28(1):010708. doi:10.11613/BM.2018.010708. PMID 29472803 (Imperiali 2018)
  76. International Council for Standardization in Haematology Expert Panel on Cytometry; International Society of Laboratory Hematology Task Force on Platelet Counting. Platelet counting by the RBC/platelet ratio method: a reference method. Am J Clin Pathol. 2001;115(3):460–464. doi:10.1309/w612-myep-fa7u-8uya. PMID 11246942 (ICSH 2001)
  77. Ishii T, Sasaki Y, Maeda T, et al. Clinical differentiation of infectious mononucleosis that is caused by Epstein-Barr virus or cytomegalovirus: a single-center case-control study in Japan. J Infect Chemother. 2019;25(6):431–436. doi:10.1016/j.jiac.2019.01.012. PMID 30773381 (Ishii 2019)
  78. Jardine L, Webb S, Goh I, et al. Blood and immune development in human fetal bone marrow and Down syndrome. Nature. 2021;598(7880):327–331. doi:10.1038/s41586-021-03929-x. PMID 34588693 (Jardine 2021)
  79. Jeffrey A, Mason G, Kerridge I, et al. Bone marrow pseudo-Gaucher cells demonstrating haemophagocytosis associated with extranodal NK/T cell lymphoma, nasal type. Br J Haematol. 2023;203(2):149. doi:10.1111/bjh.18998. PMID 37525415 (Jeffrey 2023)
  80. Jimenez-Vasquez V, Calvay-Sanchez KD, Zarate-Sulca Y, Mendoza-Mujica G. In-silico identification of linear B-cell epitopes in specific proteins of Bartonella bacilliformis for the serological diagnosis of Carrion's disease. PLoS Negl Trop Dis. 2023;17(5):e0011321. doi:10.1371/journal.pntd.0011321. PMID 37228134. Abstract only (Jimenez-Vasquez 2023)
  81. Johnston A, Brynes RK, Naemi K, et al. Differentiating benign from malignant bone marrow B-cell lymphoid aggregates: a statistical analysis of distinguishing features. Arch Pathol Lab Med. 2015;139(2):233–240. doi:10.5858/arpa.2013-0678-OA. PMID 25611106 (Johnston 2015)
  82. Ko YJ, Hur M, Kim H, et al. Reference interval for immature platelet fraction on Sysmex XN hematology analyzer: a comparison study with Sysmex XE-2100. Clin Chem Lab Med. 2015;53(7):1091–1097. doi:10.1515/cclm-2014-0839. PMID 25460288 (Ko 2015)
  83. Krause PJ, Auwaerter PG, Bannuru RR, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA): 2020 guideline on diagnosis and management of babesiosis. Clin Infect Dis. 2021;72(2):e49–e64. doi:10.1093/cid/ciaa1216. PMID 33252652 (Krause 2021)
  84. Kreitman RJ, Arons E. Update on hairy cell leukemia. Clin Adv Hematol Oncol. 2018;16(3):205–215. PMID 29742076 (Kreitman 2018)
  85. Kurucu B, Şahin G. High prevalence of pseudo-Pelger-Huët anomaly and neutrophil dysplasia in children with celiac disease: a retrospective case-control study. Children (Basel). 2026;13(9):1158. doi:10.3390/children13091158. PMID 42794178 (Kurucu 2026)
  86. Kushwaha R, Kumar A, Aggrawal K, et al. Post chemotherapy blood and bone marrow regenerative changes in childhood acute lymphoblastic leukemia a prospective study. Indian J Pathol Microbiol. 2014;57(1):72–77. doi:10.4103/0377-4929.130903. PMID 24739836 (Kushwaha 2014)
  87. Lamsfus Calle C, Schaumburg F, Rieck T, et al. Slow clearance of histidine-rich protein-2 in Gabonese with uncomplicated malaria. Microbiol Spectr. 2024;12(10):e0099424. doi:10.1128/spectrum.00994-24. PMID 39194289. Abstract only (Lamsfus Calle 2024)
  88. Langabeer SE. Can post-splenectomy thrombocytosis mask essential thrombocythaemia? EXCLI J. 2020;19:773–774. doi:10.17179/excli2020-1474. PMID 32636730 (Langabeer 2020)
  89. Lazzi S, Falini B. Ponatinib-related gelatinous transformation of the bone marrow. EJHaem. 2025;6(3):e858. doi:10.1002/jha2.858. PMID 40530261 (Lazzi 2025)
  90. Lee J, Light JJ, Koyada PK, et al. Educational case: Paget disease of bone. Acad Pathol. 2026;13(4):100289. doi:10.1016/j.acpath.2026.100289. PMID 42699346 (Lee 2026)
  91. Lee SH, Erber WN, Porwit A, et al. ICSH guidelines for the standardization of bone marrow specimens and reports. Int J Lab Hematol. 2008;30(5):349–364. doi:10.1111/j.1751-553X.2008.01100.x. PMID 18822060 (Lee 2008)
  92. Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int. 2016;36(5):481–508. doi:10.3747/pdi.2016.00078. PMID 27282851 (Li 2016)
  93. Lyons TW, Cruz AT, Freedman SB, et al. Interpretation of cerebrospinal fluid white blood cell counts in young infants with a traumatic lumbar puncture. Ann Emerg Med. 2017;69(5):622–631. doi:10.1016/j.annemergmed.2016.10.008. PMID 28041826 (Lyons 2017)
  94. Ma J, Chen Z, Cheng X, et al. Overuse of thrombopoietin receptor agonists driven by suboptimal response is associated with myelofibrosis in pediatric immune thrombocytopenia. Haematologica. 2026;111(10):3520–3524. doi:10.3324/haematol.2026.300651. PMID 42095249 (Ma 2026)
  95. Maccio U, Gianolio A, Rets AV. Granulomas in bone marrow biopsies: clinicopathological significance and new perspectives. J Clin Pathol. 2023;77(1):8–15. doi:10.1136/jcp-2023-209104. PMID 37640519 (Maccio 2023)
  96. Maccio U, Rets AV. Lymphoid aggregates in bone marrow: a diagnostic pitfall. J Clin Pathol. 2022;75(12):807–814. doi:10.1136/jclinpath-2022-208174. PMID 36150886 (Maccio 2022)
  97. Machlus KR, Italiano JE Jr. The incredible journey: from megakaryocyte development to platelet formation. J Cell Biol. 2013;201(6):785–796. doi:10.1083/jcb.201304054. PMID 23751492 (Machlus 2013)
  98. MacQueen BC, Christensen RD, Henry E, et al. The immature platelet fraction: creating neonatal reference intervals and using these to categorize neonatal thrombocytopenias. J Perinatol. 2017;37(7):834–838. doi:10.1038/jp.2017.48. PMID 28383532 (MacQueen 2017)
  99. Maharjan M, Balasubramanian P, Gupta AK, et al. Bone marrow examination in the diagnosis of infectious pathology: an often underutilized diagnostic tool. Cureus. 2026;18(5):e108330. doi:10.7759/cureus.108330. PMID 42255862 (Maharjan 2026)
  100. Mahittikorn A, Masangkay FR, Kotepui KU, et al. Quantification of the misidentification of Plasmodium knowlesi as Plasmodium malariae by microscopy: an analysis of 1569 P. knowlesi cases. Malar J. 2021;20(1):179. doi:10.1186/s12936-021-03714-1. PMID 33836773 (Mahittikorn 2021)
  101. Malengier-Devlies B, Metzemaekers M, Wouters C, et al. Neutrophil homeostasis and emergency granulopoiesis: the example of systemic juvenile idiopathic arthritis. Front Immunol. 2021;12:766620. doi:10.3389/fimmu.2021.766620. PMID 34966386 (Malengier-Devlies 2021)
  102. Mangat D, Palta A, Tahlan A, et al. The morphological landscape of bone marrow findings in visceral leishmaniasis. Cureus. 2026;18(2):e104000. doi:10.7759/cureus.104000. PMID 41878183 (Mangat 2026)
  103. Mashimoto M, Higuchi F, Okazaki S, et al. Decreased volume of bone marrow adipocytes with sparse gelatinous marrow transformation in a patient with pancytopenia with anorexia nervosa: a case report. Cureus. 2024;16(4):e58390. doi:10.7759/cureus.58390. PMID 38756270 (Mashimoto 2024)
  104. Meena SAV, Manokaran RK, Jayaraman D, et al. Infantile osteopetrosis with a CLCN7 variant: an educational case highlighting integrated diagnosis and variant interpretation. EJIFCC. 2026;37(4):753–758. PMID 42729708 (Meena 2026)
  105. Menter T, Tzankov A. Practical diagnostic approach to assess myeloid and precursor cell neoplasms on trephine bone marrow biopsies: reflection of middle European reality. J Hematop. 2025;18(1):47. doi:10.1007/s12308-025-00663-5. PMID 41107564 (Menter 2025)
  106. Mingot-Castellano ME, Canaro Hirnyk M, Sánchez-González B, et al. Recommendations for the clinical approach to immune thrombocytopenia: Spanish ITP Working Group (GEPTI). J Clin Med. 2023;12(20):6422. doi:10.3390/jcm12206422. PMID 37892566 (Mingot-Castellano 2023)
  107. Mock DM, Widness JA, Veng-Pedersen P, et al. Measurement of posttransfusion red cell survival with the biotin label. Transfus Med Rev. 2014;28(3):114–125. doi:10.1016/j.tmrv.2014.03.003. PMID 24969019 (Mock 2014)
  108. Mulatie Z, Kelem A, Chane E, et al. Diagnostic role of Sysmex hematology analyzer in the detection of malaria: a systematic review and meta-analysis. PLoS One. 2024;19(9):e0296766. doi:10.1371/journal.pone.0296766. PMID 39240990. Abstract only (Mulatie 2024)
  109. Munoz de Toro M, Fernandez-Pol S. Systematic literature review of published cases of reactive plasmacytosis in peripheral blood and bone marrow. J Clin Pathol. 2024;77(12):802–809. doi:10.1136/jcp-2024-209513. PMID 39366734. Abstract only (Munoz de Toro 2024)
  110. Naughton P, Harte JV, Lucey B, et al. Thrombocytopenia and neutropenia in Epstein-Barr virus infectious mononucleosis: a retrospective cohort study. Biomol Biomed. 2025;26(6):951–958. doi:10.17305/bb.2025.12998. PMID 41353761 (Naughton 2025)
  111. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866. doi:10.1182/bloodadvances.2019000966. PMID 31794604 (Neunert 2019)
  112. Newton LM, Fowler VM, Humbert PO. Erythroblast enucleation at a glance. J Cell Sci. 2024;137(19):jcs261673. doi:10.1242/jcs.261673. PMID 39397781 (Newton 2024)
  113. Nguyen PL, Olszak I, Harris NL, et al. Myeloperoxidase detection by three-color flow cytometry and by enzyme cytochemistry in the classification of acute leukemia. Am J Clin Pathol. 1998;110(2):163–169. doi:10.1093/ajcp/110.2.163. PMID 9704614 (Nguyen 1998)
  114. Noppen M, De Waele M, Li R, et al. Volume and cellular content of normal pleural fluid in humans examined by pleural lavage. Am J Respir Crit Care Med. 2000;162(3 Pt 1):1023–1026. doi:10.1164/ajrccm.162.3.9910050. PMID 10988124 (Noppen 2000)
  115. Noris P, Pecci A. Hereditary thrombocytopenias: a growing list of disorders. Hematology Am Soc Hematol Educ Program. 2017;2017(1):385–399. doi:10.1182/asheducation-2017.1.385. PMID 29222283 (Noris 2017)
  116. Onsongo S, Otieno K, Mathenge L, et al. The diagnostic performance of a Sysmex XN-31 automated malaria analyzer vs. expert microscopy. Int J Lab Hematol. 2025;47(4):613–621. doi:10.1111/ijlh.14456. PMID 40042316. Abstract only (Onsongo 2025)
  117. Opie J, Verburgh E, Bailly J, et al. Hematological complications of human immunodeficiency virus (HIV) infection: an update from an HIV-endemic setting. Open Forum Infect Dis. 2024;11(4):ofae162. doi:10.1093/ofid/ofae162. PMID 38601746 (Opie 2024)
  118. Pallarés M, Medina J, Garreta M, et al. Fungal infection detected from a peripheral blood smear review. Adv Lab Med. 2026;7(1):74–77. doi:10.1515/almed-2025-0131. PMID 41853781 (Pallarés 2026)
  119. Palma-Barqueros V, Revilla N, Sánchez A, et al. Inherited platelet disorders: an updated overview. Int J Mol Sci. 2021;22(9):4521. doi:10.3390/ijms22094521. PMID 33926054 (Palma-Barqueros 2021)
  120. Palo S. From morphologic obscurity to diagnostic clarity in bone marrow necrosis: a clinicopathological approach to diagnosis and etiological assessment. Iran J Pathol. 2026;21(4):638–641. doi:10.22034/ijp.2026.2087239.3644. PMID 42609749 (Palo 2026)
  121. Parmentier S, Kramer M, Weller S, et al. Reevaluation of reference values for bone marrow differential counts in 236 healthy bone marrow donors. Ann Hematol. 2020;99(12):2723–2729. doi:10.1007/s00277-020-04255-4. PMID 32935189 (Parmentier 2020)
  122. Pati HP, Gupta R, Sharma P, et al. ICH-ISHBT recommendations on synoptic reporting of bone marrow biopsy. Indian J Hematol Blood Transfus. 2026;42(5):1616–1626. doi:10.1007/s12288-026-02555-9. PMID 42712758 (Pati 2026b)
  123. Pati HP, Padhi S, Sharma P, et al. ICH-ISHBT recommendations on bone marrow aspiration/imprint smear synoptic reporting. Indian J Hematol Blood Transfus. 2026;42(5):1606–1615. doi:10.1007/s12288-026-02551-z. PMID 42712573 (Pati 2026a)
  124. Placek A, Chan RY, Vergara-Lluri M, et al. Transient stress lymphocytosis in a child: a case report and systematic review of the literature. Hematol Rep. 2024;16(3):431–439. doi:10.3390/hematolrep16030042. PMID 39051415 (Placek 2024)
  125. Popescu DM, Botting RA, Stephenson E, et al. Decoding human fetal liver haematopoiesis. Nature. 2019;574(7778):365–371. doi:10.1038/s41586-019-1652-y. PMID 31597962 (Popescu 2019)
  126. Porubsky S. Thymic hyperplasias in practice: clinical context, histological clues, and management implications. Cancers (Basel). 2025;18(1):84. doi:10.3390/cancers18010084. PMID 41514597 (Porubsky 2025)
  127. Rajagopalan SS, Dulmovits BM, Devine M, Thom CS. Inflammation, anemia, and vitamin D levels associate with infant thrombocytosis risk. Res Pract Thromb Haemost. 2026;10(4):106644. doi:10.1016/j.rpth.2026.106644. PMID 42254465. Abstract only (Rajagopalan 2026)
  128. Ralston SH, Corral-Gudino L, Cooper C, et al. Diagnosis and management of Paget's disease of bone in adults: a clinical guideline. J Bone Miner Res. 2019;34(4):579–604. doi:10.1002/jbmr.3657. PMID 30803025 (Ralston 2019)
  129. Resch E, Hinkas O, Urlesberger B, Resch B. Neonatal thrombocytopenia: causes and outcomes following platelet transfusions. Eur J Pediatr. 2018;177(7):1045–1052. doi:10.1007/s00431-018-3153-7. PMID 29705932 (Resch 2018)
  130. Rix B, Maduro AH, Bridge KS, Grey W. Markers for human haematopoietic stem cells: the disconnect between an identification marker and its function. Front Physiol. 2022;13:1009160. doi:10.3389/fphys.2022.1009160. PMID 36246104 (Rix 2022)
  131. Roberts I, Murray NA. Neonatal thrombocytopenia: causes and management. Arch Dis Child Fetal Neonatal Ed. 2003;88(5):F359–F364. doi:10.1136/fn.88.5.f359. PMID 12937037 (Roberts 2003)
  132. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393. doi:10.1182/blood-2008-07-162503. PMID 19005182 (Rodeghiero 2009)
  133. Roemer MGM, Chevallier M, van Dijk M, et al. Alder-Reilly anomaly leading to incidental diagnosis of MPS VII in an asymptomatic adult. JIMD Rep. 2026;67(6):e70128. doi:10.1002/jmd2.70128. PMID 42920760 (Roemer 2026)
  134. Rose SR, Petersen NJ, Gardner TJ, Hamill RJ, Trautner BW. Etiology of thrombocytosis in a general medicine population: analysis of 801 cases with emphasis on infectious causes. J Clin Med Res. 2012;4(6):415–423. doi:10.4021/jocmr1125w. PMID 23226175 (Rose 2012)
  135. S R S, Holla R, Rao M, et al. Are HRP2/3 deletions silently crippling malaria rapid diagnostic tests? Indian J Med Res. 2026;163(3):295–303. doi:10.25259/IJMR_2856_2025. PMID 42024904 (S R S 2026)
  136. Saini A, Sareen R, Gupta GN. High fluorescent cells on automated body fluid analysis as discriminator for malignant cell detection. South Asian J Cancer. 2025;14(4):728–738. doi:10.1055/s-0043-1776287. PMID 41473373 (Saini 2025)
  137. Salter BM, Ju X, Sehmi R. Eosinophil lineage-committed progenitors as a therapeutic target for asthma. Cells. 2021;10(2):412. doi:10.3390/cells10020412. PMID 33669458 (Salter 2021)
  138. Sam KM, Schneider HG. Evaluation of revised UK-NEQAS CSF-xanthochromia method for subarachnoid hemorrhage: outcome data provide evidence for clinical value. Clin Chem Lab Med. 2025;63(4):771–779. doi:10.1515/cclm-2024-0995. PMID 39467816 (Sam 2025)
  139. Sanchez Clemente N, Ugarte-Gil C, Solorzano N, et al. An outbreak of Bartonella bacilliformis in an endemic Andean community. PLoS One. 2016;11(3):e0150525. doi:10.1371/journal.pone.0150525. PMID 26991495. Abstract only (Sanchez Clemente 2016)
  140. Sánchez-Cortés J, Gabaldó-Barrios X. Jordans' anomaly in Chanarin-Dorfman syndrome. Adv Lab Med. 2025;6(1):118–121. doi:10.1515/almed-2024-0159. PMID 40160390 (Sánchez-Cortés 2025)
  141. Satoh K, Wada T, Tampo A, et al. Practical approach to thrombocytopenia in patients with sepsis: a narrative review. Thromb J. 2024;22(1):67. doi:10.1186/s12959-024-00637-0. PMID 39039520 (Satoh 2024)
  142. Savoia A, De Rocco D, Panza E, et al. Heavy chain myosin 9-related disease (MYH9-RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder. Thromb Haemost. 2010;103(4):826–832. doi:10.1160/TH09-08-0593. PMID 20174760 (Savoia 2010)
  143. Schmidley JW, Simon RP. Postictal pleocytosis. Ann Neurol. 1981;9(1):81–84. doi:10.1002/ana.410090116. PMID 7212671 (Schmidley 1981)
  144. Schmitz LL, McClure JS, Litz CE, et al. Morphologic and quantitative changes in blood and marrow cells following growth factor therapy. Am J Clin Pathol. 1994;101(1):67–75. doi:10.1093/ajcp/101.1.67. PMID 7506481. Abstract only (Schmitz 1994)
  145. Scramstad C, Jackson AC. Cerebrospinal fluid pleocytosis in critical care patients with seizures. Can J Neurol Sci. 2017;44(4):343–349. doi:10.1017/cjn.2016.442. PMID 28176670 (Scramstad 2017)
  146. Serwas NK, Huemer J, Dieckmann R, et al. CEBPE-mutant specific granule deficiency correlates with aberrant granule organization and substantial proteome alterations in neutrophils. Front Immunol. 2018;9:588. doi:10.3389/fimmu.2018.00588. PMID 29651288 (Serwas 2018)
  147. Shergill KK, Shergill GS, Pillai HJ. Gelatinous transformation of bone marrow: rare or underdiagnosed? Autops Case Rep. 2017;7(4):8–17. doi:10.4322/acr.2017.039. PMID 29259927 (Shergill 2017)
  148. Shrestha S, Nazy I, Smith JW, Kelton JG, Arnold DM. Platelet autoantibodies in the bone marrow of patients with immune thrombocytopenia. Blood Adv. 2020;4(13):2962–2966. doi:10.1182/bloodadvances.2020001846. PMID 32603421. Abstract only (Shrestha 2020)
  149. Siala E, Bouratbine A, Aoun K. Mediterranean visceral leishmaniasis: update on biological diagnosis. Tunis Med. 2022;100(1):13–26. PMID 35822327 (Siala 2022)
  150. Singh K, Tiwari D, Boddu R, Somasundarum V, Mishra K. Hematogones: the supreme mimicker and a cytomorphological confounder in acute lymphoblastic leukemia. J Lab Physicians. 2023;15(2):212–216. doi:10.1055/s-0042-1757586. PMID 37323612. Abstract only (Singh 2023)
  151. Singh S, Ahsan E, Saravanan G, et al. Demystifying the evaluation of a "dry tap". J Hematop. 2025;18(1):17. doi:10.1007/s12308-025-00635-9. PMID 40232604 (Singh 2025)
  152. Sjulstad AS, Brekke OL, Alstadhaug KB. Visual inspection versus spectrophotometry for xanthochromia detection in patients with sudden onset severe headache: a diagnostic accuracy study. Headache. 2025;65(1):80–89. doi:10.1111/head.14802. PMID 39087907 (Sjulstad 2025)
  153. Snower DP, Smith BR, Munz UJ, et al. Reevaluation of the periodic acid-Schiff stain in acute leukemia with immunophenotypic analyses. Arch Pathol Lab Med. 1991;115(4):346–350. PMID 1707262 (Snower 1991)
  154. Soto-Avila LM, Fernández-Sánchez H, Rodriguez-Morales AJ. Etiologies and diagnostic yield of bone marrow evaluation in adults living with HIV in Venezuela: a cross-sectional study. Viruses. 2026;18(9):992. doi:10.3390/v18090992. PMID 42797824 (Soto-Avila 2026)
  155. Summers C, Rankin SM, Condliffe AM, et al. Neutrophil kinetics in health and disease. Trends Immunol. 2010;31(8):318–324. doi:10.1016/j.it.2010.05.006. PMID 20620114 (Summers 2010)
  156. Suster D, Ronen N, Pierce DC, et al. Thymic parenchymal hyperplasia. Mod Pathol. 2023;36(8):100207. doi:10.1016/j.modpat.2023.100207. PMID 37149223 (Suster 2023)
  157. Sylvester JE, Buchanan BK, Silva TW. Infectious mononucleosis: rapid evidence review. Am Fam Physician. 2023;107(1):71–78. PMID 36689975 (Sylvester 2023)
  158. Tan Y, Cai X. Transient neutrophil morphological abnormalities in a post-chemotherapy patient receiving G-CSF. Int J Lab Hematol. 2025;47(1):11–12. doi:10.1111/ijlh.14352. PMID 39074951 (Tan 2025)
  159. Ugwu C, Palma AU, Bhat R, Taneja A. Myelodysplasia from valproic acid resolved by cessation. Case Rep Hematol. 2026;2026:5588671. doi:10.1155/crh/5588671. PMID 42602188 (Ugwu 2026)
  160. Varotto E, Munaretto E, Stefanachi F, et al. Diagnostic challenges in acute monoblastic/monocytic leukemia in children. Front Pediatr. 2022;10:911093. doi:10.3389/fped.2022.911093. PMID 36245718 (Varotto 2022)
  161. Vayne C, Guéry EA, Rollin J, Baglo T, Petermann R, Gruel Y. Pathophysiology and diagnosis of drug-induced immune thrombocytopenia. J Clin Med. 2020;9(7):2212. doi:10.3390/jcm9072212. PMID 32668640 (Vayne 2020)
  162. Vélez Pinos PJ, Saavedra Palacios MS, Colina Arteaga PA, et al. Niemann-Pick disease: a case report and literature review. Cureus. 2023;15(1):e33534. doi:10.7759/cureus.33534. PMID 36779112 (Vélez Pinos 2023)
  163. Wang E, Boswell E, Siddiqi I, et al. Pseudo-Pelger-Huët anomaly induced by medications: a clinicopathologic study in comparison with myelodysplastic syndrome-related pseudo-Pelger-Huët anomaly. Am J Clin Pathol. 2011;135(2):291–303. doi:10.1309/AJCPVFY95MAOBKRS. PMID 21228370 (Wang 2011)
  164. Wang Y, Tang XY, Yuan J, et al. Bone marrow granulomas in a high tuberculosis prevalence setting: a clinicopathological study of 110 cases. Medicine (Baltimore). 2018;97(4):e9726. doi:10.1097/MD.0000000000009726. PMID 29369209 (Wang 2018)
  165. Ward AC. The interleukin-7 receptor signaling pathway and its perturbation in immunodeficiency, autoimmune disease and lymphoid malignancy. Biomolecules. 2026;16(2):219. doi:10.3390/biom16020219. PMID 41750289 (Ward 2026)
  166. Warkentin TE, Greinacher A. Platelet-activating anti-platelet factor 4 disorders. N Engl J Med. 2026;395(5):478–491. doi:10.1056/NEJMra2502459. PMID 42441431 (Warkentin 2026)
  167. Wickham CL, Sarsfield P, Joyner MV, et al. Formic acid decalcification of bone marrow trephines degrades DNA: alternative use of EDTA allows the amplification and sequencing of relatively long PCR products. Mol Pathol. 2000;53(6):336. doi:10.1136/mp.53.6.336. PMID 11193054 (Wickham 2000)
  168. Wong J, Jackson R, Chen L, et al. Determination of age-dependent bone marrow normocellularity. Am J Clin Pathol. 2024;161(2):170–176. doi:10.1093/ajcp/aqad129. PMID 37904278. Abstract only (Wong 2024)
  169. Wu MF, Hsieh HH, Huang WC, et al. Effects of analyzer detection method, ethnicity, and reference individuals on reference interval of immature platelet fraction. Clin Lab. 2018;64(5):699–708. doi:10.7754/Clin.Lab.2018.171025. PMID 29739038 (Wu 2018)
  170. Yamane T. Cellular basis of embryonic hematopoiesis and its implications in prenatal erythropoiesis. Int J Mol Sci. 2020;21(24):9346. doi:10.3390/ijms21249346. PMID 33302450 (Yamane 2020)
  171. Zheng X, Wang H, Zhou Z, et al. Risk factors and outcomes of culture-negative peritonitis in peritoneal dialysis: 10 years' insight from a large center in northern China. BMC Nephrol. 2026;27(1):266. doi:10.1186/s12882-026-04902-4. PMID 41862882 (Zheng 2026)
  172. Zhou RW, Sangam K, Budhram A. Clinical utility of CSF correction factors for traumatic lumbar puncture in adults. Neurol Clin Pract. 2024;14(6):e200350. doi:10.1212/CPJ.0000000000200350. PMID 39185100 (Zhou 2024)
  173. Zini G, Chang YH, d'Onofrio G, et al. ICSH recommendations for monocyte cell lineage morphologic identification, nomenclature harmonization, and utilization as a biomarker. Int J Lab Hematol. 2026;48(1):12–25. doi:10.1111/ijlh.70029. PMID 41297912 (Zini 2026)
  174. Zini G, d'Onofrio G. Coronavirus disease 2019 (COVID-19): focus on peripheral blood cell morphology. Br J Haematol. 2023;200(4):404–419. doi:10.1111/bjh.18489. PMID 36203344 (Zini 2023)
  175. Zushi Y, Sasaki M, Mori A, et al. Acute monocytic leukemia diagnosed by flow cytometry includes acute myeloid leukemias with weakly or faintly positive non-specific esterase staining. Hematol Rep. 2018;10(1):7435. doi:10.4081/hr.2018.7435. PMID 29721252 (Zushi 2018)